Location of study village	Types of prevention practices reported	Frequency & motivation for bed net use	Influences on preventative health behaviours	Community suggestions for participation in malaria elimination

North Tanna	Use of bed netsClean home/personalhygieneProtective clothingTidy village/sourceInsect spray	Some reported seasonal use others reported year round use (varies at household & individual levels)Motivation to nets for both mosquito nuisance and protection from malariaNet rarely used whentravelling	Health officers most influential (VHW, nurse)Church leaders, chiefs &Village eldersTeachersMothers most influentialon health behaviours ofchildrenRisk perceptionAcceptability andPractical issues	Take advice of village leadersSet example for othersTidy village/sourcereducton activitiesUse bed netsMosquito sprayand coilsUse fire/smoke for protection outsideImprove roads to Lenakel/closer clinics for treatment

Middle Bush	Use of bed netsClean homeTidy village/sourcereductionDrinking clean waterBlanket for protectionwhen sleeping duringtravel	Mostly seasonal use of bed netsPrimary motivation ismosquito nuiscanceNet rarely used whentravelling	Doctors & health officersCheif & church leadersTeachersHousehold heads influencefamily practicesMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues	Village leaders to spread messagesLeaders to set example for othersTidy village/sourcereduction activitiesUse bed netsImprove access to earlyand effectivetreatment

South Tanna	Use of bed netsClean home/personalhygieneTidy village/sourcereductionFire/smoke as repellentBlanket for protectionwhen travelling	Some reported seasonal use others year round use (varies at household &individual levels)Motivation to use nets forboth mosquito nuiscanceand protection frommalariaNet rarely used whentravelling	Health officers Church leaders, chief and village eldersHousehold heads influencefamilyMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues	Village leaders to encourage participationTidy village/sourcereduction activitiesUse bed netsSupport IRS

Homogeneity/ Heterogeneity of responses	Homogeneity in types of protection methods used across the 3 villages	Heterogeneity between the Middle Bush village and other 2 villages due to absence of malaria	Homogeneity in influences on health behaviours across the 3 villages	Homogeneity in ideas for participation in malaria prevention across the 3 villages


Exon	Primers (3′-5′)	Annealing temperature (°C)	Buffer pH	MgCl2 (mM)	% DMSO	Fragment (bp)

1	F: GCAGATTTAAAGCAACACCACC	60	8.4	1	0	242

R: CCCCTTCAAATTATCCTCAGC

2	F: CTAGTGATTCATCGATGTAGCTC	52	8.4	1	10	370

R: TTTCCAGCTCCTCTGGTCATTGC

3	F: TGATGTCAGTTTTCAAAGTTTTCC	54	8.4	1	0	313

R: TAATTAGCAAAACTGAGAGAGTGG

4	F: GCACACATTAAATTTGTTTCTGCA	54	8.4	1.5	0	345

R: TACCACTTTGTCAGATTATAGATG

5	F: TAGTAACTCCACATTTTTCTATAC	50	8.4	1.5	0	301

R: TAAGTGCAAAGTAATAGTAACTGT

6	F: AATATTTTCAGAGTAAGCACTCAT	50	8.4	1.5	0	288

R: ACACTTTATACAATCCCAATCAAA

7	F: GTGATGTTGCTTAAAAGCATCAAAC	54	8.6	1.5	0	325

R: CTTGTAAAGAAGCAACAAGATCAAC

8	F: CCATTTTCCTGAAACACTACCCTA	52	8.4	1.5	0	377

R: TTGGGGTACAGTGCAACAGATTAG

9	F: AATTATTTGAATTTCCAGACACCT	50	8.4	1.5	0	375

R: GGGTTATTCTATGAAATTAGTCCA

10	F: GCAATTTCACTATTCTATGAAAGG	52	8.4	1.5	0	348

R: ACAGAATTGGCTACATAATGGCT


Factors	β	S.E.	aOR (95% CI)

Residence (rural vs. urban)	0.79	0.36	2.03 (1.30–4.25)

Parental history of T1DM (positive history vs. negative)	3.90	2.54	9.03 (1.02–85.32)

Mod Of Delivery (cesarean vs. vaginal)	0.75	0.43	2.13 (1.09–5.03)

Breast feeding (>6 months vs. <6 months)	−1.46	0.39	0.23 (0.11–0.50)

Introduction of cows milk in first year of life (positive vs. negative)	2.99	0.42	19.94 (8.73–45.53)

Vitamin D Supplementation in first year of life (positive vs. negative)	−2.16	0.37	0.11 (0.05–0.24)

Physical Activity (high vs. low)	−2.90	0.44	0.05 (0.02–0.12)


Substance	Reported Usage	Percent of Survey Participants

Opioid Pharmaceuticals	18	5.95%

Hallucinogens	11	3.63%

MDMA/Ecstasy	10	3.30%

Cocaine/Crack Cocaine	7	2.31%

Benzodiazepine Pharmaceuticals	6	1.98%

Other Substances	5	1.65%

Stimulant Pharmaceuticals	3	0.99%

Methamphetamine	2	0.66%

Heroin	0	0.00%


Variables	Lean	Overweight	Obese	p for heterogeneity

BMI (kg/m2)(mean)	18.5–24.9922.7 ± 1.7	25–29.9927.1 ± 1.6	≥3033.5 ± 3.8

No. of subjects (%)	246 (51)	150 (31)	77 (18)

Sociodemographic variables

 Age (years)	48 ± 16	57 ± 17	61 ± 16	<0.0001

 Female/male	122/124	66/84	49/28	<0.0001

 University degree or higher	180	89	33	<0.0001

 Household income (above median)	149	84	38	0.1

Health behaviors

 Current smoking (%)	16	11	6	0.9

 Physical activity (kJ/d/Kg)	47 ± 20	47 ± 22	43 ± 23	0.44

Health measures

 Systolic blood pressure (BP) (mm Hg)	116 ± 15	123 ± 16	126 ± 19	<0.0001

 Diastolic BP (mm Hg)	71 ± 10	75 ± 11	77 ± 11	<0.0001

Disease diagnosis

 Myocardial infarction	1	3	1	0.3

 Cancer	11	6	9	0.03

 Diabetes	3	6	9	<0.0001

 Stroke	4	0	1	0.3

 High cholesterol	21	17	17	<0.01

 High BP	19	30	29	<0.001


Time since quitting	Beneficial health changes that take place

24 h	Lungs start to clear out mucus and other smoking debris

48 h	Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved

72 h	Breathing becomes easier. Bronchial tubes begin to relax and energy levels increase

2–12 weeks	Circulation improves

3–9 months	Coughs, wheezing and breathing problems improve as lung function is increased by up to 10%

1 year	Risk of a heart attack falls to about half that of a smoker

10 years	Risk of lung cancer falls to half that of a smoker

15 years	Risk of heart attack falls to the same as someone who has never smoked


Characteristic	N	%

Pre-pregnancy nutritional status (BMI)

Underweight (<18.5 kg/m2)	84	10.9

Normal weight (18.5 – 24.99 kg/m2)	494	63.8

Overweight (25.0 – 29.99 kg/m2)	131	16.9

Obese (≥30.0 kg/m2)	65	8.4

Total weight gain

Low	209	26.9

Intermediate	298	38.4

High	270	34.7

Mode of delivery

Normal	288	49.6

Forceps	22	3.8

Cesarean section	270	46.6

Gestational age at birth

Preterm (<37 weeks)	26	4.7

Term (≥37 weeks)	527	95.3

Weight at birth

Low (<2500 g)	33	4.3

Normal (2500 g - 3999 g)	695	91.1

High (≥4000 g)	35	4.6

Pregnancy complications

None	455	54.9

Other	347	41.9

Gestational diabetes mellitus	27	3.3


Analysis	Number of plants assayed	Number of tolerant plants	Transformation frequency

Basta leaf paint	78	70	89.73%

Kanamycin/paromomycin Leaf bleach	34	32	94.12%


Plant specie	 Aa length	PTS1	pI	Molecular Mass (kDa)	Accession number

Arabidopsis thaliana	486	-SKI	7.02 	53.6	AEE73797.1

Cleome spinosa	485	-SMI	5.80	53.6	ABD96861.1

Medicago sativa	486	-SRI	5.33	53.7	AAB41553.1

Oryza sativa	480	-AKM	5.85	52.7	AJB98434.1

Pinus sylvestris	483	-SKI	6.31	53.3	ADP03057.1

Pinus pinaster	483	-SKI	6.74	53.2	ADP03318.1

Spinacia oleracea	483	-SKI	6.04	53.2	AAK51690.1

Vitis vinifera	438	-SKI	8.13	48.3 	CAN67602.1

Zea mays	480	-SKI	6.09	52.7	ACN35899.1


Resource	Brief description	Included information

Facilitator manual	Comprehensive train-the-trainer manual detailing all information required for the delivery of the program	* Introduction* Successful facilitating* Background to the research* Session guides

Manual for Dads	Handbook for fathers that includes a summary of the information from the face-to-face sessions and additional background information	* Session 1: Weight loss fundamentals for men* Session 2: Raising children in an inactive world* Session 3: Ready to rumble with dad* Session 4: Healthy eating for families - dads matter* Session 5: Fun, fitness and fundamental movement skills* Session 6: Sustaining healthy lifestyles* Session 7: Weight loss is a journey not a destination

Dad's log book	Handbook that dads use as a working document	* Program activities: Energy calculations; sedentary behaviors; goal setting; eating habits* Homework activities: Children's screen time; family fitness activity; family cooking; children's food intake; cue words; family activity* Monitoring procedures: Pedometer chart; weight loss chart; goal recording

Website user guide	Handbook to guide fathers through the setup and use of the dietary and physical activity monitoring website	* Setting up a profile* Food and exercise diary* Check in diary* Charts and reports

Kid's Handbook	Includes tasks for children to complete each week with their dads that must be signed off with their dads (space to receive a sticker from facilitators if completed)	* Kids homework activities* Recipes to cook with dad

Green slips	Homework activity slips given to fathers at the end of each session	* Activities are designed to align with the principles presented at the intervention session and any activities detailed in the Dad's log book and Kid's handbook (e.g. cooking meals with kids, family fundamental movement skills circuit, rough and tumble games with dad)


Instrument	Countries

Supply side regulation: in patent drugs

Price controls: administrative or statutory pricing	All EU Member States except Germany, UK and, to a certain extent, Sweden

External reference pricing	All EU Member States except UK, Germany, Sweden

Rate of return regulation	UK

Negotiations and price-volume agreements	France, Italy, Austria

Direct expenditure controls: payback	France, Portugal, Austria

Direct expenditure controls: price volume agreements	France

Cost-plus pricing	Spain

Supply side regulation: off patent drugs

Tendering for generics pharmaceuticals in primary care	Netherlands, Germany

Price capping for generics and linking these to the originator price	Italy, Greece, France

Supply side regulation: reimbursement methods

Positive and negative formularies	All EU Member States

Internal reference pricing	Germany, Netherlands, Czech Republic, Italy, Spain, France, Hungary

Health Technology Assessments (HTA)	UK, Sweden, Netherlands, Hungary, Poland, Finland, Estonia, Latvia, Lithuania. In France only assessment of clinical benefit

Innovative pricing and reimbursement schemes	Italy, Germany, UK, Finland

Demand side regulation: policies towards physicians

Clinical practice guidelines	All EU Member States

Compulsory generic prescribing	UK, Denmark, Estonia

Financial incentives	France, UK

Prescription monitoring and audit	Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia

Demand side regulation: policies towards pharmacies

Control of remuneration (e.g. margins, fees) including contractual arrangements	All Member States

Generic substitution	France, Italy, Spain, Sweden

Demand side regulation: policies towards patients

Cost-sharing	All EU Member States

Encouraging use of over-the counter medicines and “de-listing”	UK, Germany, Sweden, Netherlands


ATC Code	Drug classification	No. of visits 	%

G01A	Anti-infectives	5402	15.1%

M01A	Anti-inflammatory, non-steroids	3754 	10.5%

N02B	Other analgesics and anti-pyretics	2884 	8.1%

G03D	Progestogens	2871 	8.0%

A02A	Antacids	2683	7.5%

D07C	Corticosteroids, combinations with antibiotics	2090 	5.9%

R06A	Antihistamines for systemic use	1932 	5.4%

A03A	Drugs for functional bowel disorders	1866 	5.2%

J01D	Other beta-lactam anti-bacterials	1863 	5.5%

G03C	Estrogens	1837 	5.1%


Variables	Number	Percentage

Acute or chronic inflammation	36	30

Rheumatism 	33	26.6

Degeneration of valves	49	40.8

Endocarditic 	2	1.6


Analyses	Nanoemulsion	Curcumin-nanoemulsion

Size (nm)	200 ± 9.9	199 ± 0.2

Zeta potential (mV)	−40.2	−46.3

Polydispersity index (PdI)	0.248	0.179


Indicators	Value

White blood cell	5200/μL

Hemoglobin	11.3 g/dL

Platelet	103 × 103/μL

Prothrombin time	96%

Activated partial thromboplastin time	22.6 s

Aspartate aminotransferase	26 U/L

Alanine aminotransferase	20 U/L

Lactate dehydrogenase	244 U/L

Alkaline phosphatase	280 U/L

Total bilirubin	0.7 mg/dL

Total protein	6.9 g/dL

Albumin	3.9 g/dL

Blood urea nitrogen	25.6 mg/dL

Creatinine	1.05 mg/dL

Uric acid	7.3 mg/dL

Na	139 mEq/L

K	6.9 mEq/L

Cl	104 mEq/L

Total cholesterol	169 mg/dL

C-reactive protein	0.11 mg/dL

Protein induced by vitamin K absence II	61 mAU/mL

α-Fetoprotein	384 ng/mL


Key actor	Moura-Barrancos	Guadiana	Malcata	Total

Land owners (including livestock breeders)	9	9	5	23

Local council representatives	8	8	8	24

Local nature conservation technicians (administration, NGOs, fiscalization)	6	7	7	20

Land and hunting managers	6	8	2	16

Hunting guards	8	3	3	14

Nature activity users and promoters (tourism, collectors, leisure)	6	7	5	18

Lynx observers	9	-	7	16

Total	52	42	37	131

Hunter	26	19	15	60

Non-hunter	26	23	22	71


Topic	Reference	Question	Summary of the results

Knowledge	(26–42)	Differences in knowledge	Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: educational level, disadvantaged groups, etc

	(43–48)	Effective tools to improve knowledge and reduce inequalities	Differences tend to diminish after any kind intervention to inform women. Results about written material are inconclusive; short counseling showed to be effective

Coverage	(16, 49–51)	Longer screening intervals can increase the coverage for hard-to-reach population	No data are available

	(9, 52)	Access to opportunistic HPV testing could be limited by the high cost of the test in private laboratories	No data are available

	(49, 53, 54)	Self-sampling device could be used to reduce sampling costs, but could affect coverage	Only one trial conducted in Mexico. A lower coverage was achieved, but it was due to women not found at home and to whom the self-sampling was not mailed

Participation	(9, 13, 16, 17, 21, 26, 32, 50, 52, 53, 55–57)	The proposal of a new test may change the participation	Several observational studies and one trial found a small increase in participation when invited for a HPV test compared to Pap test. No data on how it will impact on inequalities

		Longer intervals could disrupt the habits, thereby of women reducing participation	No data are available

	(14, 22, 49, 53–55, 58–75)	Self-sampling device could be used to participation in screening program	Nine studies showed a positive effect of self-sampling in under-screened population. Some studies showed that the device is acceptable also among disadvantage women, even in some case to a minor extent

Compliance to screening protocols	(41)	Longer intervals could increase opportunistic over-screening	No data are available

	(9, 21, 35, 36, 57)	Referral to early rescreen after HPV positive cytology-negative test could increase use of unnecessary ascertainment	No data are available

	(17, 21, 76, 77)	Referral to early rescreen after HPV positive cytology-negative test could result in substantial loss to follow up	The compliance to early rescreen in this group of women varied among studies, showing that correct communication can reduce loss to follow up. No data about differences in socio-economic status are available

Communication of positive results	(2, 9, 78–81)	Communication of HPV positivity can induce anxiety	Several studies showed anxiety after the communication of Pap test and/or HPV positivity. Women with higher educational level are advantaged in understanding the gynecologist’s and midwife’s recommendations and explanations

	(32, 40, 79, 80, 82–84)	Communication of HPV positivity can induce changes in sexual habits	Some studies showed concern about the sexual transmission of the virus. These concerns were stronger in women of lower educational level and disadvantaged ethnic groups

	(31, 36, 84–91)	Effective ways to reduce anxiety and other adverse effects	Face-to-face counseling was preferred by women, but cannot be used only for positive results because of the anxiety caused by the understanding that the test was positive and the need to wait for the counseling. Short phone counseling only for positive was also appreciated

Interaction vaccine and screening	(38, 92–98)	Negative effect of vaccine on future screening	Only one studies reported a small proportion of girls referring that vaccination would change their attitude to screening

	(56, 99–103)	Association between vaccine and screening attitudes	Several studies showed an association between vaccine and screening attitude or between vaccination and screening coverage in mothers. Results are heterogeneous


Cytogenetic abnormality	Frequency	ASXL1 mutational frequency	SETBP1 mutational frequency	SRSF2 mutational frequency	U2AF1 mutational frequency	SF3B1 mutational frequency	Spanish cytogenetic risk stratification	Mayo–French cytogenetic risk stratification

+8	~23%	~24%	0%	~27%	0%	0%	High risk	Intermediate risk

-Y	~20%	~12% (SS)	~40%	~16%	0%	~9%	Low risk	Low risk

-7/7q-	~14%	~14%	~40%	~11%	40%	0%	High risk	Intermediate risk

20q-	~8%	~10%	0%	~11%	0%	0%	Intermediate risk	Intermediate risk

der(3q)	~8%	~2% (SS)	0%	~3%	20%	45% (SS)	Intermediate risk	Low risk

+21	~8%	~10%	0%	~5%	20%	0%	Intermediate risk	Intermediate risk

Complex and monosomal karyotypes (MK)	~10%	~4%	~20%	~8%	~40% (SS)	0%	Complex high risk. MK not included in stratification	High risk


Risk factor	Changes in capillary morphology or blood rheology

Aging	Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30]

Hypertension	Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericytes [33, 34]

Diabetes	Human: Thickened basement membranes [35, 36]. Hyperviscosity and reduced erythrocyte deformability in proportion to microvascular complications [37]Animal models: Pericyte loss and thickening of capillary basement membrane [31, 38, 39]. Glycocalyx degradation by oxidative stress, oxidized lipoproteins, and hyperglycemia [40–42]In vitro: Hyperglycemia-induced oxidative stress in the pericytic mitochondria causes pericyte apoptosis [43]

Alzheimer’s diseaseAPOE ε4 genotype	Human brain: Pericyte degeneration, pericapillary fibrosis [44]In vitro: Cultured human pericytes undergo degeneration when exposed to certain subtypes of Aβ [45]. Pericytes express Aβ receptors involved in amyloid internalization and pericyte death [46]

Nicotine use (including smoking)	Nicotine upregulates the expression of adhesion molecules in the capillary endothelium [47] and increases leukocyte rolling [48]


Authors	Contrast

*Aichorn et al., 2009	False belief > photo (question)

*Abraham et al., 2010	Belief-questions > control-questions and desire-questions > control-questions

*Bahnemann et al., 2010	ToM judgments minus appearance judgments

*Bruneau et al., 2012	ToM localizer

*Dohnel et al., 2012	Sally Anne task (true and false ToM minus reality)

Fletcher et al., 1995	ToM stories vs. Physical stories

Gallagher et al., 2000	ToM vs. non-ToM stories

Gobbini et al., 2007	False belief stories vs. physical belief stories

*Hartwright et al., 2012	False belief minus false photograph

Hynes et al., 2005	Cognitive PT minus Control

*Jenkins and Mitchell, 2010	Mentalizing scenarios > non-social scenarios

*Kobayashi et al., 2008	ToM > physical (both japanese and english language groups)

*Kobayashi et al., 2006	ToM compared with non-ToM-conjunction among language groups

*van der Meer et al., 2011	ToM high inhibition minus fixation

Mitchell, 2007	Tom minus attention cueing task

Perner et al., 2006	False belief vignettes minus photo vignettes

*Rabin et al., 2009	ToM photo minus autobiographical memory photo

Ruby and Decety, 2003	3rd person minus 1st person

*Samson et al., 2008	ToM cartoons minus non-ToM cartoons

Saxe and Kanwisher, 2003	ToM inference minus mechanical inference

Saxe and Powell, 2006	False belief minus false photograph

Saxe et al., 2006	ToM reference experiment

*Veroude et al., 2012	Others vs. self (females only)

Vollm et al., 2006	ToM minus physical causality one character

*Wolf et al., 2010	Social minus physical inference (multiple choice and silent)

Young et al., 2007	Belief minus photo

*Young et al., 2010	Mental > physical sentences

*Zaitchik et al., 2010	Belief sentences > control sentences


Maternal health service use indicator	Overall (n = 1457)	District	P value

Jhelum (n = 747)	Layyah (n = 710)

Sought at least one antenatal care (ANC) visit	96.6	97.8	95.3	0.01

Type of ANC provider

 Community Midwife (CMW)	8.3	13.8	2.4	0.00

 Doctor	57.5	57.2	57.8	0.83

 Skilled birth attendant	27.2	24.3	30.4	0.02

 Dai	4.6	2.6	6.7	0.00

Type of childbirth attendant

 CMW	7.9	12.4	3.2	0.00

 Doctor	36.1	47.6	24	0.00

 Non-physician skilled birth attendant	25.5	26.3	24.6	0.49

 Dai/traditional birth attendant	30.5	13.7	48.2	0.00

Place of delivery

 Home (home and dai home)	41.2	29.3	54	0.00

 CMW clinic/home	1.1	3.1	0.7	0.01

 Government	21.6	27.1	15.9	0.00

 Private	35.1	40.5	29.4	0.00

Satisfaction with CMW care

For ANC (n = 245)				0.05

 Very satisfied	39.5	44.2	12.9

 Satisfied	53.7	50.0	74.2

 Somewhat satisfied	2.9	1.8	9.6

 Somewhat dissatisfied/dissatisfied	4.0	4.0	3.3

For delivery (competency) (n = 109)				0.00

 Very satisfied	68.1	75.2	39.3

 Satisfied	28.5	21.1	58.5

 Somewhat satisfied	1.7	1.6	2.2

 Somewhat dissatisfied/dissatisfied	1.7	2.2	0.0


	High-energy probe	Low-energy probe	Units

Source used	22Na	99mTc

Photon energy	511	142	keV

Sensitivity	10	12	cps/kBq

Spatial resolution

 @ 1 cm in air	15	10	mm

 @ 5 cm in air	47	35	mm

Count rate range	1–50	1–100	kcps

Count rate loss	< 10%	< 10%

Shielding	n.a.	1	mmPb

Weight	500	650	g


Data	Feature	Vector	Algorithm	F1	AUC	p-value

iDASH	Bag-of-words + UMLS (5SG)	Tf-idf	SVM-Lin	0.932	0.957	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin	0.931	0.957	<0.01

	Bag-of-words + UMLS (15ST)	Tf-idf	SVM-Lin	0.930	0.957	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin-SGD	0.928	0.955	<0.01

	Bag-of-words	Tf-idf	SVM-Lin	0.927	0.955	<0.01

	Bag-of-words	Tf	NB	0.893	0.935	Baseline

MGH	Bag-of-words + UMLS (5SG)	Tf-idf	SVM-Lin	0.934	0.964	<0.01

	Bag-of-words + UMLS (15ST)	Tf-idf	SVM-Lin	0.931	0.962	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin	0.930	0.962	<0.01

	Bag-of-words	Tf-idf	SVM-Lin	0.924	0.958	<0.01

	Bag-of-words + UMLS (5SG)	Tf	LR-L1	0.915	0.953	<0.01

	Bag-of-words	Tf	NB	0.755	0.867	Baseline


Characteristic	Number (N = 1,568)	Percent (%)

Sex	915	58.4

Female	653	41.6

Male

Age group (in years)

15 – 24	410	26.1

25 – 34	595	37.9

35 – 49	563	35.9

Educational level

No formal education	142	9.1

Primary Education	1,308	83.4

Secondary Education and above	118	7.5

Marital status

Married/cohabiting	969	62.2

Single	444	27.7

Divorced/separated/widowed	155	10.1

Occupation

Student	56	3.6

Salaried employed	36	2.3

Self-employed	76	4.8

Peasant/farmer	1,370	87.4

Others	30	1.9

Radio ownership

Yes	1,211	77.2

No	357	22.8


Group session topics

Session #	Physical activity	Nutrition	Educational incentive

1	Overview of healthy nutrition	Overview of exercise	Pedometer

2	Eating healthy on a budget	Being active at home	Fruit and vegetable guide

3	Eating out and fast food	Local exercise resources	Water bottle

4	Portion control and measuring	Hidden times for exercise	Measuring cups

5	Label reading and breakfast	Injury prevention and treatment	Massage tool

6	Healthy drinks	Building strong muscles	Healthy drink ingredients

7	Mindful eating and lunch	Take a deep breath and relax	Muscle relaxation CD

8	Healthy fast food and dinner	Exercise with friends and family	Whole grain pasta

9	Eating at social events and holidays	Mini holidays for exercise	Food pamphlet

10	Healthier traditions and review	Review and social dancing	Recipe with ingredients

11	Relapse response	Review and relay games	Motivational letter

12-15	Review relapse response, problem solving, and goal setting	Social support cards and displayable health guides

<underline>Community health worker support session topics*</underline>

<underline>Nutrition</underline>

 Beverage inventory, evaluation of milk and water consumption, and goal for healthy beverages

 Evaluation of fat in cooking and goal for cooking with less fat (steaming, baking, etc.)

 Evaluation of fruit and vegetable consumption and goal for consuming more fruits and vegetables

 Evaluation of high calorie foods and goals for reduction of high calorie food or snacking

 Decision-making for shopping and meal planning

<underline>Physical activity</underline>

 Chart and practice walking route (at first environmental support session)

 Identify support network of friends and family members for exercise

 Identify exercise locations in and around home

 Select physical activity goal

 Identify new physical activities to try

*Topics may be covered in any order, but must be during the intensive intervention phase.


Feature	P. fici

Assembly size (Mb)	52

Scaffold N50 (Mb)	4

Coverage (fold)	24.5

GC content (%)	48.73

GC exon (%)	53.56

GC intron (%)	44.18

Repeat content (%)	2.97

Protein-coding genes	15,413

Gene density (genes per Mb)	296.9

Exons per gene	2.76

tRNA genes	258

rRNA genes	52

Pseudogenes	494

Transposable elements (%)	1.54


	Controls (N = 39) (%)	Cases (N = 123) %

Stage I	22 (56)	55 (45)

Stage II	14 (36)	54 (44)

Stage III	3 (8)	14 (11)

ER or PR positive/HER2 negative	33 (85)	104 (85)

ER or PR positive/HER2 positive	6 (15)	19 (15)


Mutation model	Sign test	Standardized differences test	Wilcoxon test

IAM	Hee = 20.49	T2 = 13.196	P (one tail for H deficiency) 1.000

	Hd = 0	P = 0.000	P (one tail for H excess) 0.000

	He = 40		P (two tails for H excess and deficiency) 0.000

	P = 0.000

SMM	Hee = 22.40	T2 = 11.518	P (one tail for H deficiency) 1.000

	Hd = 0	P = 0.000	P (one tail for H excess) 0.000

	He = 40		P (two tails for H excess and deficiency) 0.000

	P = 0.000


Variables	Rank†	P-value	HR	95% CI

Age	5	0.60	0.9	0.5-1.6

Male	3	0.10	2.5	0.8-7.7

Black	6	0.82	1.1	0.3-3.8

Initial creatinine ≥ 175 μmol /L	1	0.00	6.1	2.2-17

Uncontrolled hypertension	2	0.01	4.3	1.4-14

Trombotic microangiopathy	4	0.19	1.9	0.7-5.2


Container capacity, L	Number of 2MR disks	Target ppb

10	1/5	27

20	1⁄2	27

30	2/3	27

40	1	27

50	1	27


Variable	B	SE	p	OR

Theme B vs all others	3.260	.744	.017	4.64

having some TFA questions	2.816	.757	<.001	16.71

constant	-5.515	.841	<.001	.004


A	B	C	D	E	F	S	M	Range(where present)	Peak assignments*

–	–	–	–	–	1299	–	–	1299	(CH2)n deformations

–	–	–	–	1356	–	1355	–	1356	Tertiary (CH) deformation

1411	1415	1413	1413	1413	1415	–	–	1411–1415	(CH2) or (CH3)

–	1438	–	–	–	1439	–	–	1438–1439	(CH2)

1450	–	1443	1447	1447	1449	–	1445	1443–1450	(CH2), (CH)

1509	–	1509	1507	1511	–	1510	1510	1507–1511	Asymmetrical aryl ring stretch

1603	–	1603	1603	1602	1605	–	–	1602–1605	Aryl stretching vibration

1716	1724	1729	1724	1727	1719	1727	1728	1716–1729	C = O stretch of aldehydes, ketones, esters

–	–	–	–	–	–	2820	–	2820	CH bending

–	2851	2845	2856	2856	2850	–	–	2845–2856	CH antisymmetric and symmetric stretch of aliphatic compounds

–	2882	–	–	–	2881	–	–	2881–2882	CH antisymmetric and symmetric stretch of aliphatic compounds

2905	2907	2907	2908	2907	–	–	2909	2905–2909	CH antisymmetric and symmetric stretch of aliphatic compounds

–	2932	–	–	–	2932	–	2934	2932–2934	CH antisymmetric and symmetric stretch of aliphatic compounds

2939	–	–	2941	2938	2938	2939	–	2938–2941	Antisymmetric C–H stretch in –OCH3 symmetric CH stretch

2963	2966	2966	2968	2966	2967	–	2969	2963–2969	CH antisymmetric and symmetric stretch of aliphatic compounds

3074	–	–	–	3073	–	–	–	3073–3074	(=C–H)


	6-month change score	Difference of two groups (I – C)

	Intervention Group	Control Group

N*		N*

Laboratory data

HbA1c (% (mmol/l)	224	−1.0 (−1.2 to −0.7)	217	−0.5 (−0.8 to −0.3)	−0.4 (−0.8 to −0.1)

(−10.5 (−13.2 to −8.0))		(−5.9 (−8.7 to −3.2))	(−4.6 (−8.4 to −0.9))

Social support

Social support score from Diabetes Care Profile (points)	222	0.2 (−0.0 to 0.4)	217	0.1 (−0.1 to 0.3)	0.1 (−0.2 to 0.4)

SF-12 Scores

PCS-12 (points)	203	0.6 (−0.4 to 1.6)	196	1.6 (0.6 to 2.6)	−1.0 (−2.4 to 0.4)

MCS-12 (points)	203	1.4 (0.3 to 2.5)	196	−0.2 (−1.3 to 0.9)	1.6 (0.1 to 3.2)

Program evaluation (Post-intervention only)

Participants’ perception of empowerment attributable to the program at follow-up (points) †	226	4.4 (4.4 to 4.5)	216	4.3 (4.2 to 4.4)	0.1 (0.0 to 0.2)


 	 	Value

Age (years)	 	41 (18–79)

Gender (n)	Male	64

 	Female	73

Marital status (n)	Single	26

 	Married	111

Education (n)	Primary school	69

 	Secondary school	17

 	High school	31

 	University	20


Qualitative Theme	Exemplar Quotation(s)

Less Willing to Honestly Disclose SU/MH with PROs

 Harder to disclose to computer	“It takes a lot for a person to express how they feel when you can be face to face with somebody. Emotionally and physically...being face to face with her ... It’s easier.” (Patient 20, Not Retained, MH only)

 Fear of Provider Judgement	“Other patients see [will start] missing their appointments because they ashamed of what the doctor seen. Especially when you bring it to their attention...They’ll start shying away from the clinic” (Patient, Retained, SU only).

More Willing to Honestly Disclose SU/MH with PROs

 Easier to disclose to computer	“That would give the doctor herself an extra little something that well, I can read this and maybe they don’t want to open to me, but they’ll open up to this. So I think that’d be real good.” (Patient 19, Retained, SU only)


Modification	Role	Species/System	Region/Residue(s) 	Enzyme	Reference(s)

Ubiquitination	Target for proteasome dependent degradation	Human Mcm10(HeLa, U2OS)in vivo	440–525783–803843–875(regions that can mediate degradation)	Cul4-DDB1-VprBP	[93,95,97,98]

Ubiquitination	Functional regulation during S-phase	Yeast Mcm10(Saccharomyces cerevisiae)	K85, K122, K319, K372, K414, K436	Not identified	[67,100]

Phosphorylation	Unknown function	Human Mcm10 (HeLa)	T85, S93, S150, S155, A182, S203, S204, A210, S212, T217, R286, T296, S488, S548, S555, S559, S577, S593, Y641, S644, T663, S706, S824(* only sites identified in more than 2 datasets are listed)	Not identified, except T85 which is ATR or ATM dependent.	[93,101,102,103,104,105,106,107,108,109,110,111,112]

Phosphorylation	Replisome stability	Xenopus extract	S154, S173, S206, S596, S630, S690, S693	S-CDK	[113]

Acetylation	Protein stability and DNA binding	Human Mcm10	K267, K312 *, K318, K390 *, K657, K664, K668, K674 *, K681 *, K682 *, K683 *, K685 *, K737 *, K739 *, K745 *, K761 *, K768 *, K783, K847 *, K849 *, K853, K868, K874	p300 (acetylase)SIRT1 * deacetylase)* indicates subset of SIRT1 target residues	[62]


Risser’s stage	Original method	French method

Stage 0	Micro-ossification (2)1 Gas shadow (1)2	Micro-ossification (2)1 Gas shadow (1)2

Stage 1	Skip ossification (2)3 Gas shadow (1)2	Gas shadow (1)2 Skip ossification (2)3

Stage 2	Skip ossification (1)3 Miscalculation of excursion (4)4	Skip ossification (1)3 Miscalculation of excursion (2)4

Stage 3	Miscalculation of excursion (5)4	Micro-fusion (4)5

Stage 4	Miscalculation of excursion (1)4 Micro-fusion (3)5	Skip ossification (2)3 Pseudo-fusion (10)6Micro-fusion (4)5

Stage 5	Skip ossification (2)3 Pseudo-fusion (14)6


 	Skin to calyx distance

 	≤75mm	>75mm	P value

Number	140	130

Gender	 	 	0.823

Male	88	80

Female	52	50

Mean age (years)	43.09±12.5	45.4±12.4	0.129

Mean body mass index (kg/m2)	25.7±3.5	26.6±5.3	0.090

Mean stone size (mm)	21.7±5.8	22.8±6.0	0.143

Stone location	 	 	0.077

Complex stone	60	57

Pelvis	31	34

Lower	40	30

Middle	8	6

Upper	1	3

Operation side	 	 	0.745

Left	76	68

Right	64	62

Degree of hydronephrosis	 	 	0.682

0	6	4

1	72	66

2	54	54

3	6	6

4	2	0

Previous renal stone treatment	 	 	0.853

SWL	22	21

PNL	14	17

Open renal stone surgery	11	13


Characteristic	Improvisation	Composition

Context	Public or private	Private

Individual/group	Individual or group	Individual or group (less frequent)

Development	Continuous, linear, real-time act, extemporaneous creation	Continuous or discontinuous act, mediated creation

Experimentation	Extemporaneous experimentation; it can provide suggestions to composition	Reasoned experimentation

Abilities	Performing and compositional	Compositional

Processes	Anticipation, use of repertoire, emotive communication, feedback, and flow	Planning, translating from the sound to graph, idea generation, organization and construction, revision

Reversibility	Irreversible action, it cannot be changed	Reversible action, it can be changed until the final draft

Revision	It cannot be reviewed, but only adjusted in real-time during the performance with the feedback	It can be reviewed and improved

Control	Control of individual variables but not of group variables	Overall control of the score and of the complexity of the compositional process

Feedback	Real-time feedback	Feedback without real-time pressure

Process dynamics	Interactive process. It has an adaptable nature, it allows you to answer to context variables, it can be adjusted instantly. Challenge between performers, taking risks	Fix product. The composition can be interpreted but it is not possible to change the notes of the score

Communication	The author has a direct communication with the audience. It is more authentic and real than composition	The author has a communication with the audience mediated by the performer(s) who interprets his/her ideas


Comorbidities and outcomes	Estimate (mean or proportion)	95% CI

Number of comorbidities	7.54	(7.53-7.55)

Charlson comorbidity category

 Low (1–2)	0.29%	(0.26%-0.31%)

 Medium (3–4)	17.29%	(17.12%-17.46%)

 High (5+)	82.42%	(82.25%-82.60%)

Inpatient death	3.15%	(3.08%-3.23%)

Inpatient length of stay (days)	5.22	(5.20-5.25)

Inpatient cost (2009 $US)	$11,313.28	($11,233.77-$11,329.80)


Strains and conditions	Throughput (Mbp)	Absolute counts	Ratios

 	 	Reads aligned on reference genome	Uniquely aligned reads	Ratio considering DB110 HP as reference (all reads)	Ratio considering DB110 HP as reference (unique reads)

DB110 28 MPa (DB110 HP)	582	16.621.219	5.836.186	1.00	1.00

DB110 0.1 MPa (DB110 LP)	584	16.690.818	3.050.616	1.00	0.52

TW30 28 MPa (TW30 HP)	611	17.466.471	5.692.495	1.05	0.97

TW30 0.1 MPa (TW30 LP)	479	13.699.146	4.517.864	0.824	0.77


Cost category	Cost (USD)	Percentage

Project costs of program implementation:

 Support structure	57,794	14.2

 Salary	196,839	48.3

 Medicine	144,020	35.3

 Supplies	9,301	2.3

 Total financial cost	407,954	100.0

Estimated unit costs of program implementation:

 Unit annual cost per WAJA	3,610

 Per capita cost	1.16


Parameters	Definitions

Patient characteristics	Age, weight, height, body mass index (BMI), medical insurance status and performance status

Hospitalisation	LOS (length of hospitalisation post-operation), the procedure performed, diagnosis, operating time, name of surgery, intra-operative estimated blood loss

Post-operation	Time to full tolerance of free fluids (days), time to full tolerance of solid food (days), time to drain removal (days) hospitalisation expenses

Complications

Infection	Wound infection, lung infection, intraperitoneal infection, operation space infection (fever, mild abdominal pain without radiographic abnormalities)

Post-operative nausea and vomiting (PONV)	It was recognised that nausea and vomiting are common side effects of surgical recovery

Ileus	Is a disruption of the normal propulsive ability of the gastrointestinal tract

Post-operative haemorrhage	Evidence of blood loss from drains or based on ultrasonography

Post-operative thrombosis	Evidence of blood thrombosis based on ultrasonography

APACHE II score	Acute Physiology and Chronic Health Evaluation II


Risk-factors	Level	Categorization

Herd1	1,2,3,4

Sow-related factors

Parity	Young	1st parity

Mature	2nd-7th parity

Litter size	Large2	Gilts: >15 piglets, Sows: >18 piglets

Small	Gilts: <16 piglets, Sows: < 19 piglets

Stillborn	Many	>1 piglet

Few	0-1 piglets

Clinical disease	Yes	Mastitis and/or temp > 39.5°C and/or leg problems and/or vulva discharge3

No	None of the above

Piglet-related factors4

Gender	Male

Female

Birth weight	Continuous scale

Faecal consistency	Liquid	Watery or liquid consistency of rectal contents

Normal	Creamy, firm or solid consistency of rectal contents and if no faeces on swab

Flanks	Hollow	Area behind ribs turned inwards

Normal	Area behind ribs followed the line of the ribs

Hair coat	Rough	Hair coat appeared dull

Normal	Hair coat did not appear dull


Site of metastases	PTC-GD	Euthyroid

Bone	2 (6.8%)	1 (0.4%)

Lung	0	2 (0.8%)

Bone + lung	2 (6.8%)	4 (1.6%)

Local recurrence + lung	0	3 (1.3%)

Local recurrence + lung + bone	0	3 (1.3%)

Local recurrence	1 (3.4%)	4 (1.7%)


Parameter	Description	Baseline cohort (n = 43)	PD cohort (n = 40)

Age at sample draw	Median age (range)	72 (37–83)	63 (35–88)

Adjuvant endocrine therapy (%)	No	26 (60)	26 (65)

Yes, tamoxifen only	10 (23)	9 (23)

Yes, tamoxifen + AI	5 (12)	4 (10)

Yes, AI only	2 (5)	1 (2)

Adjuvant chemotherapy (%)	No	34 (79)	28 (70)

Yes	9 (21)	12 (30)

Neoadjuvant therapies (%)	No	43 (100)	40 (100)

Number of previous lines endocrine therapy lines for MBC (%)	0	43 (100)

1		22 (55)

2		12 (30)

≥3		6 (15)

Endocrine therapy after start (BL cohort) or before PD (PD cohort) (%)	AI	30 (70)	25 (63)

Tamoxifen	13 (30)	7 (17)

Fulvestrant		8 (20)

Previous endocrine therapy lines for MBC (in case of inclusion at PD on ≥second‐line endocrine therapy) (%)	Yes, AI only		9 (23)

Yes, AI + tamoxifen		6 (15)

Yes, tamoxifen only		3 (7)

Progression on the current line (%)	Yes	35 (81)	40 (100)

CTC count	Median count (range)	81 (6–32492)	21 (5–2837)


	Area

Khagrachari	Cox’s Bazar	Bandarban	Rangamati	Netrokona	Total	Frequency

A (1,900 bp)	10	56	6	1	2	75	0.735

B (1,400 bp)	1	2	1	0	1	5	0.049

C (1,100 bp)	2	5	2	0	0	9	0.088

Mixed	2	10	0	0	1	13	0.127


	Mean	95% HPD	Posterior probability

PB2	August 2016	June – October 2016	0.9992

PB1	August 2016	July – October 2016	0.9993

PA	July 2016	May – October 2016	0.9995

HA	September 2016	July – October 2016	0.9997

NP	May 2016	October 2015 – October 2016	0.9997

NA	May 2016	June – October 2016	0.9689

M	August 2016	June – October 2016	0.4849

NS	September 2016	June – October 2016	0.9995


Conceptual definition 	Operational definition

Prostate cancer knowledge—Participants’ understanding of CaP disease, prevention and detection. 	Ten questions assessed participants’ prostate cancer knowledge using a True/False/Don’t Know scale. Each correct response had 1 point and incorrect response or ‘I don’t know’ response had 0 point. Higher score indicated high knowledge of prostate cancer information.

Prostate cancer early detection behaviour—CaP information seeking behaviour and CaP screening.	An index of Prostate Cancer Detection Behaviour was created by combining (sum) the responses of participants on prostate cancer screening by DRE in the last year (5 if Yes, and 0 if No); prostate cancer screening by PSA in the last year (5 if Yes, and 0 if No); prostate cancer information seeking behaviour (measured on a 5-point Strongly Agree–Strongly Disagree scale); prostate cancer discussion with a physician (measured on a 5-point Strongly Agree–Strongly Disagree scale); and paying attention to prostate cancer information (measured on a 5-point Strongly Agree–Strongly Disagree scale). The index score ranged from 0 to 25.

Prostate cancer screening intention—Participants’ expressed likelihood of screening for CaP in the future	Three questions were used to measure intention. For example, participants responded to the question: ‘Within the next year, I will get tested for prostate cancer with the Digital Rectal Examination (DRE)’ on a strongly disagree (1)–strongly agree (5) scale, with higher score indicating high intention.

Decisional conflict—Participants’ state of uncertainty about the course of action to take relative to CaP screening [34].	O’Connor’s scale [34] provided the items for decisional conflict. The scale used for this study assessed CaP screening uncertainty (3 items) and factors contributing to uncertainty (7 items) on a strongly disagree (1)–strongly agree (5) scale. An example of the screening uncertainty measure is ‘I’m unsure what to do when it comes to prostate cancer screening’. Lower score on this scale indicates high uncertainty. An example of the factors contributing to uncertainty measure is ‘I feel I know the risks and side effects of prostate cancer screening’. Higher score on this scale indicates greater number of factors contributing to uncertainty.

Satisfaction with the W.O.R.D video 	Participants’ satisfaction was assessed by three questions. For example, participants responded to the statement, ‘The information I received from the Prostate Cancer Education video can best be described as’ using a Very Unsatisfactory (1)–Very Satisfactory scale (5) with higher score indicating high satisfaction.

Quality of the W.O.R.D video 	Participants’ perceived quality was assessed by three questions. For example, participants responded to the statement, ‘The Prostate Cancer Education video can best be described as superior’ using a strongly disagree (1) strongly agree (5) scale, with higher score indicating high quality rating.

General assessment of the W.O.R.D video 	Using a ‘Yes’, ‘No’ and ‘I can’t say’ scale, participants responded to ten questions focused on general assessment of the video. Examples were: Was the information provided by the video useful to you? Did you experience any difficulty with the video? In your opinion, would you say that the video is credible?


Input	Processing	Output

Alignment	Export to a different format	Alignment

Alignment	Remove sequences >80 % identical and columns with conservation <0.9	Alignment

Alignment	Construct neighbour-joining tree using Kimura distance correction	Distance matrix

Distance matrix	Reconstruct tree	Tree

Alignment	Apply bootstrap analysis	Bootstrap trees


Source	Country	Filling (Years)	Remarks

R Franceys, et al. [15]	Various	15–25	Design recommendations for household properties

J Pickford [17]	East Africa	Over 30	Reported at a house hold level

P Morgan [53]	Zimbabwe	Over 30	Household latrine

DA Still and K Foxon [107]	South Africa	20	Design recommendation

	South Africa	5–9	Empting time for most (85 %) pit latrines. Lower and higher filling rates were also noted

I Günther, et al. [56]	Uganda	5	Study in low income areas of Kampala, Uganda (Slums)

RN Kulabako, et al. [108]	Uganda	<1	Low laying areas of peri-urban settlements in Kampala

K Adubofour, et al. [109]	Ghana (slums in Kusami metroplis)	4.2	Average filling time

>10	High income areas

0.25	Low income areas

E Appiah-Effah, et al. [57]	Ghana (Ashanti region)	6–10	Low income area in Ashanti region


MONITORING LAYER	INFORMATION LAYER	INTERCHANGE LAYER

Capture Subsystem	Analysis Subsystem	Visualization & Control Subsystem

MDP	Probes

Communication events:	Composite probe: 	Merging traces	Web-based visualization	XML records with TimeStamp, Metadata and Radio packet	Ethernet based platform

Transmission_Error

Routing_Error	Attached monitor node (Traps)

Transmission_success	Trace Analysis on the merged trace, based on several analysis tools	SQL database

Captured_Frame	Single probe: Sniffers

Mote_state


Poroscientific Model 740	Relative uncertainty (k = 1)	Absolute uncertainty	Percent contribution	Comments

LP CFV stagnation pres., P0 = 570.03 kPa	(× 10−6)	(Pa)	(%)

Calibration transfer standard for static pres.	17	9.7	2.1	Traceable to NIST Pres. and Vacuum Group

Drift limit	60	34.2	25.6	< 0.01 % in 6 months, assume rect. distrib.

Residuals, hysteresis, thermal effects	100	57.0	71.3	From cal. records, experiments

Dynamic pres. Unc.	12	6.7	1	Est. based on unc. of 10 % u(M) and 5 %

RSS	118	67.5	100


Bacteria	Total (N = 221)

Gram-negative organisms

 Klebsiella species	83 (38%)

 Escherichia coli	72 (33%)

 Pseudomonas aeruginosa	10 (5%)

 Enterobacter species	8 (4%)

 Proteus species	3 (1%)

 Citrobacter species	3 (1%)

 Serratia species	1 (1%)

 Acinetobacter species	1 (1%)

Gram-positive organisms

 Enterococcus species	18 (8%)

 Streptococcus species	17 (8%)

 Staphylococcus species	2 (1%)

Anaerobes

 Bacteroides species	3 (1%)


Subscale	Experimental group (n = 25)	Control group (n = 23)

Anxiety

 Week 0	6.3 ± 3.2	6.5 ± 3.4

 Week 4	4.1 ± 2.9∗#	6.1 ± 3.2

Depression

 Week 0	4.9 ± 3.8	4.8 ± 3.1

 Week 4	3.1 ± 2.8∗∗##	4.6 ± 2.9

Total

 Week 0	10.9 ± 4.1	10.8 ± 3.9

 Week 4	7.1 ± 3.1∗∗##	9.8 ± 3.4


Acceptance Number	Drug	Date	Company	Progress

JXSL1600007	Nivolumab	17 February 2016	Bristol-Myers Squibb	In Assessing

JXSL1500068	7 December 2015

JXSL1300032	20 May 2013	In Clinic

JXSL1600009	Pembrolizumab	29 February 2016	Merck	In Assessing

JXSL1600005	16 February 2016

JXSL1500074	31 December 2015

JXSL1500058	30 September 2015

JXSL1500040	28 July 2015

JXSL1500020	25 May 2015

CXSL1400138	JS001-PD-1	21 January 2015	ShangHai JunShi	In Clinic

CXSL1400153	SHR-1210	19 January 2015	ShangHai HengRui

CXSL1500096	BGB-317	11 December 2015	BeiGene	In Assessing

CXSL1600016	Genor PD-1 Antibody	7 April 2016	Genorbio


Inputs	Outputs

Solar irradiance spectra	Radiance spectrum

Gas absorption and scattering cross sections	Jacobians (partial derivatives of the radiance spectrum with respect to each of the state vector elements)

Atmospheric state	-

Surface state	-

Instrument line shape function	-

Aerosol optical properties	-


Imaging direction	Treatment	Sheep (n = 5)	Pigs (n = 3)

Dorsal/Ventral	Baseline	14	15

Hypertonic	1	7

Isotonic	0	6

Mannitol	0	3

Lateral	Baseline	14	10

Hypertonic	3	2

Isotonic	4	3

Mannitol	0	4

Other	Upside down	2	0

At 24 h	1	0

Lung	0	4

		39	51


Subject terms	Titles

synuclein	alpha-synuclein

alpha synuclein

alpha

protein

aggregation

deep brain	deep brain stimulation

deep

stimulation

brain stimulation

subthalamic

lewy	lewy bodies

lewy bodies

bodies

lewy body

dementia

monoamine oxidase	monoamine oxidase

oxidase

monoamine

mao

b

mitochondrial	oxidative stress

oxidative

complex i

oxidative stress

stress


Score	Criteria

0	Active and positive engagement with the assessor or a positive response to the stimuli introduced

1	Relaxed or passive response

2	Acceptance after a few attempts and eventual tolerance

3	Overexcitement

4	Dog was attempting to avoid the assessor or the stimuli or used mouthing

5	Exhibition of fear, tonic immobility, or escape from the arena


Organisms	Patients

Coagulase-negative Staph.	14 (35%)

Staph. Aureus`	7 (17.5%)

Gram-negative rods	5 (12.5%)

Enterococcus	2 (5%)

Coliform Bacilli	3 (7.5%)

Diphteroid Bacilli	1 (2.5%)

No Pathogens identified	8 (20%)


Adverse effect	Outcome	Upper risk limit (%)

		Low-dose methylprednisolone	High-dose methylprednisolone

Acute severe allergy	Lethal	0.24	0.00a

Life-threatening	2.65	1.18

Cardio-pulmonary distress	Lethal	0.33	0.79

Persistent	0.02	0.39

Life-threatening	0.86	1.71

Diabetes	Lethal	0.02	0.53

Persistent	0.86	1.05

Life-threatening	0.07	0.13

Gastrointestinal haemorrhage	Lethal	0.26	0.39

Persistent	0.13	0.13

Life-threatening	0.37	0.79

Hepatotoxicity	Lethal	0.11	0.13

Persistent	0.11	0.53

Life-threatening	0.29	0.66

Myopathy	Persistent	0.46	0.79

Life-threatening	0.07	0.13

Osteonecrosisb	Persistent	0.57	1.58

Pancreatitis	Lethal	0.04	0.13

Psychosis	Persistent	0.04	0.13

Life-threatening	0.07	0.13

Seizure	Lethal	0.09	0.39

Persistent	0.13	0.00a

Life-threatening	0.13	0.13

Ventricular arrhythmia/cardiac arrest	Lethal	0.55	1.05

Persistent	0.09	0.13

Life-threatening	0.86	1.18

Totalc	Lethal	1.65	3.42

Persistent	2.43	4.73

Life-threatening	5.36	6.04


MIGS ID	Property	Term	Evidence codea

	Classification	Domain Bacteria	TAS [7]

		Phylum Firmicutes	TAS [8–10]

		Class Firmibacteria	TAS [8, 9, 11]

		Order Bacillales	TAS [8, 9, 12, 13]

		Family Bacillaceae	TAS [8, 9, 13, 14]

		Genus Bacillus	TAS [8, 9, 13, 15]

		Species Bacillus cereus	TAS [8, 9, 13, 16]

		Strain FORC_005

	Gram stain	Positive	TAS [17, 18]

	Cell shape	Rod	TAS [17, 18]

	Motility	Motile with peritrichous flagella	TAS [17, 18]

	Sporulation	Endospore-forming	TAS [8]

	Temperature range	10 °C–50 °C	TAS [8, 17]

	Optimum temperature	28–35 °C	TAS [8]

	pH range; Optimum	4.9–9.3; 6.0–7.0	TAS [17]

	Carbon source	Glucose, Aesculin	TAS [19]

MIGS-6	Habitat	Ubiquitous; especially in soil	TAS [17, 18]

MIGS-6.3	Salinity	0–7.5 % NaCl (w/v)	TAS [17]

MIGS-22	Oxygen requirement	Facultative anaerobes	TAS [17, 18]

MIGS-15	Biotic relationship	free-living	NAS

MIGS-14	Pathogenicity	Diarrhea, emesis in human	NAS

MIGS-4	Geographic location	Incheon, South Korea	IDA

MIGS-23	Isolation	Korean soy sauce braised fish-cake with quail-egg	IDA

MIGS-5	Sample collection	March 2014	IDA

MIGS-4.1	Latitude	37.27 N	IDA

MIGS-4.2	Longitude	126.42 E	IDA

MIGS-4.4	Altitude	Not reported


RAFK, RAF-RAFK

RAFPH, RAFPH-RAF~{p1}

RAF, MEK-RAF~{p1}, RAF-RAFK, RAFPH-RAF~{p1}, MEK~{p1}-RAF~{p1}, RAF~{p1}

MEKPH, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2}

MEK, MAPK-MEK~{p1, p2}, MEK-RAF~{p1}, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2}, MAPK~{p1}-MEK~{p1, p2}, MEK~{p1}-RAF~{p1}, MEK~{p1}, MEK~{p1, p2}

MAPKPH, MAPKPH-MAPK~{p1}, MAPKPH-MAPK~{p1, p2}

MAPK, MAPK-MEK~{p1, p2}, MAPKPH-MAPK~{p1}, MAPK~{p1, p2} MAPK~{p1}-MEK~{p1, p2}, MAPK~{p1}, MAPKPH-MAPK ~{p1, p2},


Comparison		χ2 statistics	p-value

IPI vs. NCCN-IPI	IPI	6.46	0.0110

	NCCN-IPI	1.69	0.1941

IPI vs. GELTAMO-IPI	IPI	10.32	0.0013

	GELTAMO-IPI	3.25	0.0712

NCCN-IPI vs. GELTAMO-IPI	NCCN-IPI	0.06	-*

	GELTAMO-IPI	1.60	-*


Animals	Saline	TNBS alone	TNBS + RTP

SD rats	31.5 ± 2.16	41.8 ± 3.22	31.9 ± 1.18

BALB/c mice	33.7 ± 1.13	42.9 ± 2.20	35.1 ± 3.24


IOFB location	Number of cases (%)

In the vitreous	11 (52.38 %)

In the retina	7 (33.33 %)

Perforating	3 (14.28 %)


Type of interview	In-depth interviews	Focus group discussions

Members of HIV serodiscordant couples

N	42	25 (total participants – 4FGDs)

Age, Median (IQR)	31 (28–38)	32(28–35)

% Female	21 (50%)	14 (56%)

% HIV positive	21 (50%)	20 (80%)

Children, Median (IQR)	1 (1–2)	1 (0–1)

Providers (participating in key informant interviews)

N	20

Gynaecologist	11 (55%)

 Fertility clinics	5

 Jointly public and private clinics	4

 Safer conception research sites	2

Nurse counsellors	5 (25%)

 Safer conception research sites	3

 Public health hospitals	2

Clinical Officers	2 (10%)

 Safer conception research sites	1

 Public health hospitals	1

Counsellors	2 (10%)


Sampling sites	Functional type	Vehicle and personnel	Greenbelt coverage rate	Air pollution

SSC	Shed used to stay chicken waiting for slaughtering	A few transport vehicles with chickens about 10 times h−1	~50%	Serious air pollution

EPV	Entrances to personnel and transport vehicles with products	Flow of transport vehicles, and some flow of personnel at commuting time	<5%	A little air pollution

GB	Green belt	Little flow of vehicles and personnel	>95%	Little air pollution


COL4A3 polymorphism	PolyPhen prediction (score)	SIFT prediction (score)

G43R	possibly damaging (1.800)	not tolerated (0.00)

P141L	probably damaging (2.250)	tolerated (0.40)

E162G	benign(0.024)	tolerated (0.64)

D326Y	probably damaging (2.025)	tolerated (0.08)

H451R	benign (1.426)	tolerated (0.54)

P574L	probably damaging (2.250)	tolerated (0.19)

COL4A4 polymorphism	PolyPhen prediction (score)	SIFT prediction (score)

P482S	benign (1.125)	tolerated (0.71)

G545A	benign (1.350)	not tolerated (0.01)

M1327V	benign(0.017)	tolerated (0.13)


S/N	Communities	Number of health facilities	Population size (2010 projection)	Major source of water supply	Means of waste disposal	Means of faecal disposal

Public	Private	Mission	Other

1	Moniya	6	4	0	0	28,990	• Well water is the major source	• Indiscriminate dumping at dump sites and drainages	• Most use latrine at home

2	Ojoo	2	13	0	0	35,737	• Well water is the major source	• Indiscriminate dumping at dump sites and drainages in some areas	• Most use latrine at home

• Private refuse collector are engaged by some areas

3	Alagbafo	1	1	0	1	22,635	• Well water and spring are the major sources of water although water pipe runs through but disconnected	• Refuse containers provided by the government	• Most use latrine at home

4	Foko	1	3	0	0	29,279	• Well water is the major source of water although water pipe runs through the community but irregular	• Indiscriminate dumping at dump sites and drainages in some areas	• Indiscriminate disposal of fecal matter through the drainage or dumping site

5	Inalende	0	3	0	1	24,279	• Well water is the major source of water although water pipe runs through the community but irregular	• Indiscriminate dumping at dump sites and drainages in some areas	• Most dispose their fecal matter through the drainage or dump site

6	Odo-Ona/Apata	4	7	2	0	55,429	• Pipe borne water irregular	• Indiscriminate dumping at dump sites and drainages in some areas	• Most use latrine at home

• Well water is the major source

7	Olorunsogo	1	6	0	2	38,475	• Well water is the major source	• Indiscriminate dumping at dump sites and drainages in some areas	• Most use latrine at home

8	Olunloyo	1	2	0	0	25,531	• Well water is the major source and some have borehole	• Indiscriminate dumping at dump sites and drainages in some areas	• Most use latrine at home


Reference	n	Subjects/methods	Exposure Measurement (PC; CC, CS)	Intervention (RCT)	Cancer type	Gene/s	Locus	Effect

Al-Hilal et al., 2013 [14]	367	6-month RCT/M + F, 45–70 year		EPA + DHA; 0.45, 0.9 or 1.9 g/day		FADS1 + FADS2	rs174537	↓D5D activity associated with T variant allele; ↑D5D activity in TG, TT with increasing doses; no association for D6D

Fradet et al., 2009 [12]	Control 478; case 466	CC/M, mean age 65 year	FFQ		Prostate	COX2	rs4648310	G allele correlated with aggressive PCa when n-3 FA intake was low, and low risk with high intake

Gago-Dominguez et al., 2004 [49]	Control 670; case 258	CC/F, 45–74 year	SQ FFQ		Breast	GSTM1, GSTT1, GSTP1	multiple	Lower activity genotypes associated with higher BCa protection with ↑ intake of marine n-3 FA

Habermann et al., 2013 [11]	Control 912; case 712	CC/M + F, 30–79 year	CARDIA questionnaire		Rectal	ALOX12	rs11571339	G allele associated with↓rectal cancer risk in those with low n-3 PUFA intake (NS)

Habermann et al., 2013 [11]	Control 1900; case 1543	CC/M + F, 30–79 year	CARDIA questionnaire		Colon	ALOX15	rs11568131	AA genotype have ↓risk of colon cancer with↑ intakes of n-3 PUFA (NS)

Habermann et al., 2013 [11]	Control 1900; case 1543	CC/M + F, 30–79 year	CARDIA questionnaire		Colon	COX1	rs10306110	Low EPA/DHA intake associated with higher colon cancer risk in variant allele carriers only

Hedelin et al., 2006 [50]	Control 1130; case1499	CC/M, 35–79 year	FFQ		Prostate	COX2	rs5275	C allele at locus rs5275 correlated with ↓risk of PCa with high intake of fatty fish

Hester et al., 2014 [13]	30	CS/Caucasian F, 21–65 year	Serum FA			FADS1	rs174537	T variant correlated with lower AA; GG genotype associated with ↑LTB4 + 5-HETE

Hog et al., 2013 [37]	122	3 year PC/M, 35–59 year	Blood serum			FADS1, FADS2 + FADS3	rs174537 (FADS1); rs174575, rs2727270 (FADS2), rs1000778 (FADS3)	rs174537GG had ↑AA, AA/DGLA, DPA, LDL, oxLDL + ↓ETA. Rs17453 had↓AA, AA/DGLA, EPA, DPA, EPA/ALA + urinary PGF2a

Poole et al., 2007 [51]	Control 626; case 716	CC/M + F, 30–74 year	FFQ		Colorectal	COX1	Phe17Leu	Modest↓risk of CRC for carriers of P17 with higher fish intake; L17 carriers have ↓risk of CRC with lower intake

Poole et al., 2010 [52]	Control 582; case 483	CC/M + F, 30–74 year	FFQ		Colorectal	PGES	rs7873087	Carriers of T allele have ↓risk of CRC with ↑fish intake

Poole et al., 2010 [52]	Control 582; case 483	CC/M + F, 30–74 year	FFQ		Colorectal	EP4	Val294Ile	Carriers of Ile variant showed correlation between ↑fish intake and ↑CRC risk

Porenta et al., 2013 [53]	108	6-month RCT/CRC at risk M + F	2 day FR + 24 h recall	Healthy People 2010 diet or Mediterranean diet	Colon	FADS cluster	rs174556 and rs174561 in FADS1, rs383445 in FADS2 and rs174537 of the FADS1/2 intragenic region	Wild-type alleles associated with lower AA in colonic mucosa in persons on Mediterranean Diet


Instrument A	Time 1	Time 2	Intervention	Time 3	Difference score	Exercise test Result

Subject 1	8	9	Verum	15	+6	Much improved

Subject 2	9	8	“”	15	+7	Much improved

Subject 3	8	9	“”	15	+6	Much improved

Subject 4	9	8	“”	15	+7	Much improved

Subject 5	8	9	Placebo	8	-1	Unchanged

Subject 6	9	8	“”	9	+1	Unchanged

Subject 7	8	9	“”	8	-1	Unchanged

Subject 8	9	8	“”	9	+1	Unchanged

Instrument B	Time 1	Time 2		Time 3	Difference score	Exercise test Result

Subject 1	5	5	Verum	5	0	Much improved

Subject 2	9	9	“”	9	0	Much improved

Subject 3	13	13	“”	13	0	Much improved

Subject 4	17	17	“”	17	0	Much improved

Subject 5	5	5	Placebo	5	0	Unchanged

Subject 6	9	9	“”	9	0	Unchanged

Subject 7	13	13	“”	13	0	Unchanged

Subject 8	17	17	“”	17	0


Reference	Population	N	RRT	Mortality	Prognostic factors for hospital mortality

Mixed population (solid and hematological tumors, including bone marrow transplantation)

Berghmans et al. (15)	Solid: 50%	32	CVVHDF	ICU: 50%	Number of organ failure

Hemato: 50%	Hospital: 53%

BMT: 28%

Salahudeen et al. (5)	Solid: 38%	199	C-SLED	Day 30: 65%	SOFA score, pH, mean blood pressure

Hemato: 62%

BMT: 18%

Mixed population (solid and hematological tumors, excluding bone marrow transplantation)

Maccariello et al. (13)	Solid: 73%	118	IRRT daily conventional	ICU: 70%	Number of organ failure

Hemato: 27%	IRRT daily extended	Hospital: 78%

CRRT

Darmon et al. (7)	Solid: 7%	94	CRRT	ICU: 43.6%	LOD score, late RRT (>24 h after ICU admission)

Hemato: 78%	IRRT	Hospital: 51.1%

Other: 15%	6 months: 65.4%

Soares et al. (14)	Solid: 75%	98	IRRT conventional	Hospital: 64–86%	–

Hemato: 25%	IRRT extended

CRRT

Hematological tumors

Letourneau et al. (12)	BMT: 100%	14	CVVHDF	–	–

IRRT

Lanore et al. (11)	BMT: 11%	43		ICU: 72%	ARF secondary to sepsis, SAPS score, mechanical ventilation support

Benoit et al. (9)	BMT: 22.4%	50	IRRT	ICU: 79.6%	–

CRRT	Hospital: 83.7%

6 months: 86%


Metal	PFP soluble metals (μg metal/g PM)	Fresno soluble metals (μg metal/g PM)b

Co	< 3.2	n/a

Cr	< 0.84	n/a

Cu	< 1.0	344 ± 137

Fe	< 25	262 ± 32

Mn	< 1.8	397 ± 56

Ni	< 3.4	n/a

V	< 0.68	17 ± 3

Zn	7.8 ± 4.9	n/a


	Before SVA onset (n = 30)	After SVA onset (n = 30)	p

Systolic arterial pressure, mmHg	114 [97–127]	97 [86–118]	0.076

Diastolic arterial pressure, mmHg	58 [51–63]	58 [47–64]	0.513

Mean arterial pressure, mmHg	77.0 [70.0–87.0]	73.0 [58.5–80.5]	0.056

Arterial pulse pressure, mmHg	54 [39–70]	42 [31–57]	0.081

Heart rate, beats/min	99 [87–118]	140 [123–165]	<0.001

Dobutamine dose, μg/kg/mina	7.5 [5.0–10.0]	7.5 [5.0–10.0]	>0.99

Norepinephrine dose, mg/ha	1.7 [0.3–3.0]	1.8 [0.5–4.5]	0.010

Epinephrine dose, mg/ha	1.3 [0.5–2.0]	1.5 [0.0–3.0]	0.655


		Number of clones	Number of heteroinsertion	Number of homoinsertion	Efficiency of heteroinsertion	Efficiency of homoinsertion

Eed	LNL insertion	88	17	4	19.3%	4.5%

FNFL insertion	190	33	5	17.4%	2.6%

SRCAP	LNL insertion	94	65	3	69.1%	3.2%

FNFL insertion	96	70	2	72.9%	2.1%


Characteristics

Characteristics of the children		N	%

Age (n = 1067)	- 2 or 3 years old	227	21%

	- 4 years old	335	31%

	- 5 years old	328	31%

	- 6 years old	177	17%

Girls (n = 1068)		537	50%

First in birth order (n = 1039)		498	48%

Medical conditions (n = 1068)	- Preterm infant	96	9%

	- Hospitalisation after birth	81	8%

	- Asthma	156	15%

	- Wearing of glasses	146	14%

	- Auditory disorders	63	6%

	- Allergy	214	20%

	- Behavioural disorder	44	4%

	- At least one surgical intervention	225	21%

	- Other medical conditions	70	7%

Long term medication use (n = 1068)		73	7%

Frequency of administrating over the counter drugs without medical advice (n = 1062)	- Never	168	16%

	- Rarely	311	29%

	- Often	509	48%

	- Almost every time my child is ill	74	7%

Under homeopathic treatment (n = 1043)		549	53%

Advice from a pharmacist within the last 12 months (n = 1051)		445	42%

		Mean	SD

N. of primary care consultations within the last 12 months (n = 1029)		5.9	4.6

Parental characteristics		N	%

Single parent family (n = 1066)		136	13%

Rural place of residence (n = 1064)		217	20%

Occupation (n = 1056)	- Disadvantaged (workers, unemployed)	151	14%

	- Moderately advantaged (self-employed, employees)	563	53%

	- Advantaged (managers and executives)	342	33%

Education level (n = 1037)	- Elementary and secondary	285	27%

	- High school diploma ("Baccalauréat")	238	23%

	- Lower tertiary	235	23%

	- Higher tertiary	279	27%

Annual family income (n = 949)	- < 14 000 €	168	18%

	- 14 000 to 19 999 €	203	21%

	- 20 000 to 29 999 €	286	30%

	- 30 000 to 39 999 €	170	18%

	- ≥ 40 000 €	122	13%

		Mean	SD

Age of the respondent in year (n = 1058)		34.0	5.0

Parental stress level (n = 1040)		4.9	2.3


Procedure	Total volume (mL)	Total protein (mg)	Total activity (UI)a	Specific activityb (UI mg−1)	Purificationc (fold)

Crude extract	300	1302.3	215220	165.3	1

Ammonium Sulphate ppt.	22	43.9	13501.4	307.5	1.86

Dialysis	21	39.2	12559.9	320.4	1.94

DEAE-cellulose	12	6.37	6811.2	1069.3	6.47

Sephadex G-100	9	2.9	4599.1	1585.9	9.6


Gene name	Gene symbol	Comments	Statistics

Log2 fold change	q value

Spermidine synthetase	Srm	Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])	3.68	0.00016

Ornithine decarboxylase 1	Odc1	Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])	2.52	0.00016

Spermine synthetase	Sms	Synthesizes polyamines important in granule biogenesis and homesostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47])	0.54	0.0045

Basic helix-loop-helix family, member A15	Bhlha15	Important transcription factor in forming mature secretory granules in a variety of specialized secretory cells (Tian 2010 [72])	3.42	0.00016

Rab5c, member of Ras oncogene family	Rab5c	Key regulator of mast cell granule fusion during biogenesis (Azouz 2014 [48])	0.62	0.00032

Mannose-6-phosphate receptor	M6pr	Transports glycosylated proteins, such as lysosomal hydrolases and TNF, into vesicles (Coutinho 2012 [50], Olszewski 2006 [73])	0.43	0.00016

Adaptor protein 1A complex	Ap1m1	Protein necessary for the sorting of proteins into vesicles and secretory granule maturation (Bonnemaison 2014 [49])	0.36	0.0033

ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c	Atp6v0c	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	0.69	0.00016

ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H	Atp6v1h	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	0.52	0.00016

ATPase, H+ transporting, lysosomal V0 subunit a2	Atp6v0a2	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	0.46	0.00016

ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H	Atp6v1a	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	0.42	0.020

ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e1	Atp6v0e	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	0.32	0.0044

ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D	Atp6v1d	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	−0.24	0.038

ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2	Atp6v1g2	Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011)	−1.84	0.00016

Lysosomal trafficking regulator	Lyst	Important regulator of granule formation (Durchfort 2012 [95], Hammel 2010 [52])	−1.29	0.00016

Solute carrier family 18, member 2	Slc18a2	Transports histamine and serotonin into granules (Merickel 1995 [96])	−0.92	0.00016


Histone	Modification 1	Modification 2	Modification 3	Modification 4	Intensity average 6xHIS-Ibd1 (4 repetitions)	Intensity average 6xHIS-G9a (2 repetitions)

H3	K9ac	K14ac			0.95	0.02

H2a	K5ac	K9ac	K13ac		0.92	0.01

H4	R3me2s	K5ac	K8ac	K12ac	0.90	0.00

H4	K5ac	K8ac	K12ac	K16ac	0.89	0.03

H3	K9me3	K14ac			0.88	0.01

H3	S10P	K14ac			0.88	0.04

H4	K5ac	K8ac	K12ac		0.84	0.01

H3	T11P	K14ac			0.82	0.01

H2a	S1P	K5ac	K9ac	K13ac	0.82	0.01

H2a	S1P	K9ac	K13ac		0.81	0.01

H3	R2me2s	K4me2	R8me2a	K9me2	0.19	0.96

H3	R2me2a	K4me1	R8me2a	K9me2	0.18	0.94

H3	R2me2a	K4me2	R8me2a	K9me2	0.18	0.90

H3	K4ac	R8me2s	K9me1		0.21	0.84

H3	R2me2a	K4me2	R8me2a	K9me1	0.19	0.83

H3	R2me2a	K4me3	R8me2a	K9me2	0.18	0.80

H3	R2me2a	K4ac	R8me2a	K9me2	0.28	0.79

H3	R2me2a	K4me3	R8me2a	K9me1	0.19	0.79

H3	R2me2s	K4ac	R8me2a	K9me1	0.16	0.76

H3	R2me2s	K4me2	R8me2s	K9me1	0.17	0.76


Characteristic	n	%

Area of practice

GP/FP	117	27

GP/FP with enhanced area	72	17

Specialist	219	51

Other1:	6	1

Not specified	12	3

Number of years in practice

0 to 5	40	9

6 to 10	39	9

11 to 15	45	11

16 to 20	59	14

21 or more	230	54

Not specified	13	3

Region of practice

Atlantic	38	9

Quebec	100	23

Ontario	128	30

Prairies	70	16

BC	64	15

Territories	6	1

Not specified	20	5

Community where practicing

Urban	226	53

Rural	92	22

Both	96	23

Not specified	12	3

Language of survey completion

English	388	91

French	38	9


Bacteria	MIC (mg/mL)

IxPE	IxCE	IxME	IxWE

Bacillus subtilis (MTCC111)	2	>2	0.125	1

Staphylococcus aureus (MTCC3160)	>2	>2	1	>2

Streptococcus mutant (MTCC890)	>2	1	2	2

Escherichia coli (MTCC443)	2	1	2	>2

Klebsiella pneumoniae (MTCC109)	>2	>2	0.25	>2

Pseudomonas aeruginosa (MTCC741)	2	2	0.5	2


Subject	Age enrollment(years)	GMFCS level at enrollment	GMFM-66 change over 2 years	Abnormalmovements	Typography

1	1.7	IV	4	Spasticity with dystonia	Q

2	2.4	II	8	Spasticity	D

3	5.1	I	19	Spasticity with dystonia	H (Lh)

4	1.2	IV	4	Spasticity with dystonia	Q

5	4.0	II	2	Spasticity with dystonia	H (Lh)

6	4.4	III	4	Spasticity	D

7	2.3	II	11	Spasticity	H (Rh)

8	1.4	II	17	Spasticity	H (Lh)

9	1.1	I	16	Spasticity with dystonia	H (Rh)

10	3.7	II	11	Spasticity	H (Rh)

11	1.5	IV	2	Spasticity with dystonia	Q

12	3.8	IV	5	Spasticity with dystonia	Q

13	2.1	II	15	Spasticity	D

14	2.8	II	13	Spasticity with dystonia	H (Lh)

15	2.8	II	5	Spasticity	D

16	1.4	IV	6	Spasticity predominant, mixed with dystonia	Q

17	3.0	III	22	Spasticity predominant, mixed with spasticity	T (LUE)


Compound	Class	PIM inhibition selectivity	Development	Disease

SGI-1776	imadizaopyridazine	IC50: 7 nM PIM1, 363 nM PIM2, 69 nM PIM3, 44 nM FLT-3 and 34 nM Haspin [107].	Failure in phase I clinical trials by cardiotoxicity	Non-Hodgkin lymphoma

SMI4a	benzylidene-thiazolidene-2,4-dione	IC50: 21 nM PIM1, 100 nM PIM2 [113].	Preclinical	Acute myeloid leukemia

Selective vs. 56 kinases [114].

LGB321	3-(S)-amino-piperidine pyridyl carboxamide	IC50: 0.001 nM PIM1, 0.0021 nM PIM2, and 0.0008 nM PIM3 [106].	Recruiting patients for clinical trials	Multiple myeloma

AZD1897		IC50: 3 nM PIM1,2 and 3 [115].	Preclinical	Acute myeloid leukemia

SEL24-B58	Benzoimidazol	IC50: 31 nM PIM1, 154 nM PIM2, 152 nM PIM3. Selective in a panel of 299 kinases with the exception of haspin, HIPK and CLK kinases [117].	Preclinical	Leukemic monocyte lymphoma

AZD1208	thiazolidene	IC50: Pim-1 0.4 nM, Pim-2 5.0 nM and Pim-3 1.9 nM [115].	Recruiting patients for clinical trials	Acute myeloid leukemia


Upper Asymptote	Lower Asymptote	Sig Diff	Point of Inflection	Slope	Fit

0.99	0.48	< 0.05	3.36	−1.75	0.15


Age stratum	(%)

 39 years or younger	41

 40–49 years	42

 50 years or older	15

 Missing data	2

Sex

 Female	15

 male	85

Fields of practice

 Pediatrics	2

 Family practice	11

 General internal medicine	44

 Specialty internal medicine	21

 Surgery-related	7

 Emergency medicine	9

 The other fields	7

Size of employing facilities

 Office-based clinic	24

 1–100 beds	13

 101–250 beds	17

 251–500 beds	17

 501 or more beds	28


Genotypesa	Number of seedlings tested	Average resistance score	Significanceb

Reaction to BPH biotype 4 (2009–2014)

 CR2711–76	201	2.33	a

 Jaya	207	7.99	b

 F1 (Jaya/CR2711–76)	52	1.33	a

 PTB-33	206	4.03	a

Reaction to Laguna BPH colony (2013–2015)

 CR2711–76	199	3.87	b

 Jaya	176	8.91	a

 F1 (Jaya/CR2711–76)	24	2.88	b

 Rathu Heenati	210	3.11	b

 TN-1	272	9.01	a


Chromosomal region	Fragile site (FS)	FS typea	BAC-probe	Co-localization of FA breakpoints and FS

1p13.3	FRA1N	Aphidicolinb	RP11-242D10	+

1q21.2	FRA1F	Aphidicolin	RP11-301 M17	+

1q42.2	Near FRA1H	Azacytidin	RP11-109G24	−

2q35	FRA2U	Aphidicolin	RP11-316O14	+

3p14.2	FRA3B	Aphidicolin	RP11-129 K20	+

3p21.31	FRA3H	New nomenclaturec	RP11-787O14RP11-159A17	+

3q27.1	FRA3C	Aphidicolin	RP11-110C15	+

5q13.2	FRA5K	New nomenclatured	RP11-497H16	+

5q33.2	FRA5O	New nomenclatured	RP11-265I24RP11-494C5	+

7q22.3	FRA7F	Aphidicolin	CTB-20D2	+

7q32.3	FRA7H	Aphidicolin	RP11-138A9RP11-36B6	+

11q13	FRA11H	Aphidicolin	RP11-449G14	+

14q24.3	FRA14G	Aphidicolinb	RP3-414A15	+

16q22.1	FRA16C, FRA16B	Aphidicolin	RP11-106 J23	+

16q23	FRA16D	Aphidicolin	RP11-358 L22	+

18q21.3	FRA18B	Aphidicolin	RP11-15C15	+


Stage of prostate cancer	Hormonal agent	Function	Year of FDA approval	Reference

Advanced, hormone naïve	Goserelin acetate	GnRH agonist	1989	[27, 28]

Leuprolide acetate	GnRH agonist	1989	[27, 29]

Histrelin acetate	GnRH agonist	1991	[27, 30]

Triptorelin pamoate	GnRH agonist	2000	[27, 31]

Abarelix	GnRH antagonist	2003	[27, 48]

Degarelix	GnRH antagonist	2008	[27, 49]

Bicalutamide	AR antagonist	1995	[27, 126]

Flutamide	AR antagonist	1989	[27, 127]

Castrate-resistant	Abiraterone acetate	CYP17 inhibitor	2011b	[27, 94]

2012a	[96, 99]

Enzalutamide	AR antagonist	2012b	[27, 101]

2014a	[102, 128]


MIGS ID	Property	Term	Evidence codea

	Classification	Domain Bacteria	TAS [38]

		Phylum “Nitrospirae”	TAS [38]

		Class “Nitrospira”	TAS [38]

		Order “Nitrospirales”	TAS [38]

		Family “Nitrospiraceae”	TAS [1, 38]

		Genus Leptospirillum	TAS [39]

		Species Leptospirillum ferriphilum	TAS [5]

		Strain Sp-Cl	TAS [5]

	Gram stain	Negative	TAS [5]

	Cell shape	Curved rod	IDA

	Motility	Motile	TAS [5]

	Sporulation	Non-spore forming	TAS [5]

	Temperature range	25° to 45 °C	NAS

	Optimum temperature	30° to 37 °C	NAS

	pH range, optimum	1.3 to 2.0; NA	IDA

	Carbon source	CO2	IDA

MIGS-6	Habitat	chloride, metal-rich and acidic environment	IDA

MIGS-6.3	Salinity	0-12 g/L Cl-	IDA

MIGS-22	Oxygen requirement	Aerobic	TAS [5]

MIGS-15	Biotic relationship	Free-living	IDA

MIGS-14	Pathogenicity	None	TAS [5, 22]

MIGS-4	Geographic location	Spence mine, Atacama Desert, Chile	IDA

MIGS-5	Sample collection	2007	IDA

MIGS-4.1	Latitude	22°.81 S	IDA

MIGS-4.2	Longitude	69°.26 W	IDA

MIGS-4.4	Altitude	1700	IDA


SNPs	Allele	α-helix	Extended strand	β-turn	Random coil

c.271C > T	C	32.92	13.04	4.35	49.69

T	32.3	13.04	5.59	49.07


Health Behaviour	Total number	No. aimed at general population	No. aimed at community, school or work places	No. aimed at targeted populations or individuals

Smoking	48	5	6	Young people (11)Smokers (26)

Physical Activity	24	4	1	Young people (6)Older people (2)Adults over 18 years(8)

Alcohol	15	4	0	Young people (2)Pregnant women (1)Drink drivers (3)Problem drinkers (4)

Healthy eating	13	0	3	Young people (4)Older people (1)Pregnant women (1)Non specific (6)

Illicit drug use in young people	4	0	4	0

Sexual risk taking in young people	8	0	8	0


	Alfalfa	High nitrate-containing barley	Low nitrate-containing barley	NPA-containing milkvetch	NPOH-containing milkvetch

Crude protein (%)	17.3	13.8	6.4	10.0	9.6

Digestible crude protein (%)	12.6	9.4	2.5	5.8	5.4

Acid detergent fiber (%)	35.5	35.4	31.4	32.4	34.8

Neutral detergent fiber (%)	38.8	45.0	46.9	38.3	37.8

Total digestible nutrients (%)	60.2	59.1	59.5	60.0	58.1

Net energy lactation (Mcal/kg)	1.36	1.32	1.34	1.34	1.30

Net energy maintenance (Mcal/kg)	1.45	1.43	1.43	1.45	1.39

Net energy gain (Mcal/kg)	0.73	0.70	0.70	0.73	0.68

In vitro true digestibility (%)	75.7	80.4	68.5	85.3	82.3

Ash (%)	10.2	9.3	5.4	7.4	7.9

Relative feed value	146.7	126.8	127.7	154.7	152.0

Nitratea (%)	0.16	1.69	0.23	0.15	0.03

Mineral analysis (NIR)

Calcium	1.22	0.69	0.48	0.72	0.77

Magnesium	0.29	0.15	0.04	0.11	0.11

Phosphorus	0.39	0.29	0.16	0.25	0.23

Potassium	2.92	2.23	1.52	1.64	1.50


Strain

Bifidobacterium adolescentis DSM 20083T

Bifidobacterium adolescentis DSM 20086

Bifidobacterium adolescentis DSM 20087

Bifidobacterium animalissubsp. lactis NRRL B-41405

Bifidobacterium animalissubps. animalis NRRL B-41406T

Bifidobacterium bifidum DSM 20456T

Bifidobacterium breve DSM 20091

Bifidobacterium breve NRRL B-41408T

Bifidobacterium catenulatum DSM 20224

Bifidobacterium longumsubsp. infantis ATCC 15697T

Bifidobacterium longumsubsp. longum NRRL B-41409T

Bifidobacterium longumsubsp. suis NRRL B-41407T

Bifidobacterium pseudocatenulatum DSM 20439

Bifidobacterium pseudolongumsubsp. globosum DSM 20092T

Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20094

Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20095

Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20099T


University & Library	Responded to phase 2

1. Charles Drew University of Medicine & Science, Health Sciences Library	✓

2. Loma Linda University Medical Center, Jesse Medical Library & Information Center

3. Oregon Health and Science University, Library	✓

4. Stanford University Medical Center, Lane Medical Library

5. University of Arizona (Tucson Campus), Arizona Health Sciences Library	✓

(University of Arizona (Phoenix Campus) Partnership of U of A & ASU medical school dissolved mid-project. ASU counted as part of U of A)

6. University of California, Davis, Carlson Health Sciences Library

7. University of California, Irvine, Science Library	✓

8. University of California, Los Angeles, Biomedical Library	✓

(University of California, Riverside program is developing, with most services provided by UCLA and therefore, counted under UCLA)

9. University of California San Diego, Biomedical Library	✓

10. University of California, San Francisco, Library	✓

11. University of Colorado, Health Sciences Library	✓

12. University of Hawaii at Manoa, Health Sciences Library

13. University of Nevada Reno, Savitt Medical Library	✓

14. University of New Mexico School of Medicine, Health Sciences Library and Informatics	✓

15. University of Southern California, Norris Medical Library	✓

16. University of Utah, Eccles Health Sciences Library	✓

17. University of Washington, Health Sciences Library	✓


	Distribution between categories	Assumed hospitalization rate

No-test scenario		44.6%

Test scenario

 sFlt-1/PlGF ratio ≥ 85 at weeks 20 + 0–33 + 6, or ≥ 110 from week 34 onwards	19.60%	70.0%

 sFlt-1/PlGF ratio > 38 − < 85 at weeks 20 + 0–33 + 6, or > 38 − < 110 from week 34 onwards	16.20%	57.6%

 sFlt-1/PlGF ratio ≤ 38	64.20%	1.5%


Library	Restriction enzyme	BAC vector	No. clones	Average insert size (kb)	Insert range (kb)	Genome coverage*	HICF fragments (avg)	Control clones	Successful fingerprints

TC_Bba	HindIII	pIndigoBAC536	36864	145	90-185	10×	120.2	768	31864

TC_BBb	EcoRI	pIndigoBAC536	36864	120	40-160	10×	102.1	768	32218

TC_BBc	MboI	pIndigoBAC536	36864	140	80-180	10×	120.4	768	31304


Parameter	Value

Self-inductance	L = 6 [mH]

Rated current	I = 8 [A] (AC, 50/60 Hz, sinus wave)

Current density	J < 3 [A/mm2]

Ambient temperature	θa = +40 [°C]

Self-resonance frequency range	fcrit = 80 ÷ 140 [kHz]


Variable	OR	95 % CI	P-value

Clinical history

 No recent history of UTI	3.8	1.3–11.4	0.02

Clinical symptoms

 Nausea/vomiting	0.4	0.1–1.4	0.14

Type of UTI, symptoms

 Cystitis, no other non-urinary symptoms	1

 Cystitis, with back or adnominal pain symptoms only	11.4	2.1–63.0	0.01

 Cystitis, with vaginal discharge	12.1	1.1–137.5	0.05

 Cystitis, with other combinations of non-urinary symptoms	0.1	0.0–1.1	0.06

 Pyelonephritis (fever or flank pain present)	2.7	0.8–9.3	0.12


Characteristics	n (%)

Knowledge of modifiable risk factors

 Don't know any risk factor	27 (3.8)

 Only one risk factor	89 (12.4)

 A total of two risk factors	302 (41.9)

 Good level of knowledge*	302 (41.9)

Knowledge of symptoms of heart attack

 Don't Know	586 (81.4)

 List 1 symptom	93 (12.9)

 List at least 2 symptoms	41 (5.7)


 	 	Univariate analysis	Multivariate analysis

Variable	Threshold	Unadjusted OR	CI	Adjusted OR	CI	P value

Glucose variability (SD)	NA	5.9	0.9 to 37	10.4	1.3 to 86	.03

GCS	Every 1 point	1.1	0.8 to 1.4	0.5	0.2 to 0.99	.04


Group	n	Clinical pregnancy (case), %	Abortion (case)	Multiple pregnancy (case)	Average treatment cycle

LE group	52	16 (30.8%)	2	2	4.1±0.5

CC group	52	17 (32.1%)	3	3	3.9±0.2

LE + HMG group	52	29 (55.7%)a	2	5	2.9 ± 0.3b

χ2/F	-	-	-	-	17.241

P	-	-	-	-	<0.001


	Data sources	Health care organization characteristics

Country	Revenue/income	Practice costs	Remuneration system	Gate-keeping

Belgium	Interest group	Interest group	Fee-for-service	No

Denmark	Interest group and government agency	Interest group and government agency	Fee-for-service	Yes

Finland	WHO (2000) and independent organization	-	Mainly salary, some additional fee-for-service and capitation fee	Yes

France	Government agency	Tax office	Fee-for-service	No

Germany	Independent organization	Independent organization	Fee-for-service	No

Netherlands	Interest group	National statistics office (based on tax data)	Capitation and fee-for-service1)	Yes

Sweden	Interest group	-	Salary	No

U.K.	Independent organization (1995, 2000), government agency (2005)	Independent organization (1995, 2000), government agency (2005)	Capitation, since 2004 additional quality related payments	Yes


	WOMEN	MEN

	Core	Boost	Core	Boost

	%	%	%	%

Self-assessed general health

Very good	33	21	36	24

Good	45	51	44	48

Fair	14	23	14	24

Bad	6	4	5	3

Very bad	2	1	1	1

P-value		<underline>0.000</underline>		<underline>0.000</underline>

Very good/good	78	72	79	72

Fair/bad/very bad	22	28	21	28

P-value		<underline>0.000</underline>		<underline>0.000</underline>

N	833	2701	736	2181

Portions of fruit and vegetables

 Less than 1	5	4	8	6

 1 to 2	26	15	26	17

 3 to 4	27	27	28	24

 5 or more	42	55	38	54

P-value		<underline>0.000</underline>		<underline>0.000</underline>

N	833	2647	735	2133


Tissue	RNA expression	Tissue	RNA expression

Whole brain	•	Lung	•

Cerebral cortex	•••	Placenta	•

Frontal lobe	••	Bladder	••

Parietal lobe	••	Uterus	••

Occipital lobe	•	Prostate	•

Temporal lobe	•	Testis	•

Postcentral gyrus	•	Ovary	•

of cerebral cortex		Liver	•

Pons	•	Pancreas	•••

Cerebellum left	•	Adrenal gland	•••

Cerebellum right	••	Thyroid gland	••

Corpus callosum	•••	Salivary gland	••••

Amygdala	••	Mammary gland	•

Caudate nucleus	•	Esophagus	•

Hippocampus	•	Stomach	•

Medulla	•	Duodenum	••

oblongata		Jejunum	•••

Putamen	•	Ileum	••

Substantia nigra	•	Ileocecum	•

Accumbens	••	Appendix	-

nucleus		Colon, ascending	•

Thalamus	••	Colon, transverse	•

Pituary gland	•	Colon, descending	•

Spinal cord	•	Rectum	•

Heart	••	Fetal brain	•

Aorta	•	Fetal heart	••

Artrium left	••	Fetal kidney	•••

Artrium right	••	Fetal liver	•••

Ventricle left	••••	Fetal spleen	•

Ventricle right	••	Fetal thymus	•

Interventricular	••	Fetal lung	•

septum		Promyelocytic leukaemia,	•

Apex of the heart	••••	HL-60

Kidney	•	Hela S3	•

Skeletal muscle	•	Chronic myelogenous	••

Spleen	•	leukaemia, K-562

Thymus	••	Lymphoblastic leukaemia,	••

Peripheral blood	•	MOLT-4

leukocyte		Burkitt's lymphoma, Raji	•

Lymph node	•	Burkitt's lymphoma, Daudi	•

Trachea	•


	Rank of correct class

	1	2	3	4

Single-localized only	88.8a	92.2	94.5	96.3

CYT-NUC: 1 correct	88.2a	96.1	99.5	100.0

CYT-NUC: both correct		66.5a	82.9	96.3

All multi-localized: 1 correct	81.9a	92.0	96.1	97.4

All multi-localized: both correct		59.7a	73.8	83.2


Characteristics	Matrilineal	Patrilineal

Age (years)	M	F	M	F

 Mean	41	31	40	29

 20–29	0	2	0	3

 30–39	3	5	3	4

 40–49	4	0	4	0

Years living with HIV

 1–5	2	2	7	7

 6–10	5	5	0	0

Average number of children couples had after an HIV diagnosis	2	1

Average number of children couples have in their households	4	4

Couples with HIV+ children	2	0


Category

Total number of reads	1,366,749

Total length of reads (bp)	625,825,203

Total number of reads cleaned	1,361,424

Total length of reads cleaned (bp)	598,655,879

Number of reads placed	1,302,023

Number of singletons	10,992

Total length of singletons (bp)	3,714,066

Average length of singletons (bp)	337

Largest singleton (bp)	692

Number of contigs	39,088

Total length of contigs (bp)	22,806,009

Average length of contigs (bp)	583

Largest contig (bp)	6,401

Average read coverage of contigs	24


control	condition	YKOaux	BCprot	PBprot

SC	control	3	3	3

SC	ADE–	3	3	3

SC	ARG–	3	3	3

SC	HIS–	0	3	3

SC	LEU–	0	3	3

SC	LYS–	3	2	3

SC	MET–	3	3	3

SC	SER–	3	2	3

SC	THR–	3	2	3

SC	TRP–	3	3	3

SC	URA–	0	3	3

SC	MM*	3	4	5

SC	MM + URA	0	1	1

YPD	control	11	14	12

YPD	cisplatin, DNA cross-linking agent	3	4	3

YPD	CCCP, protonophore inhibitor of oxidative phosphorylation	3	3	3

YPD	FCCP, protonophore inhibitor of oxidative phosphorylation	3	3	3

YPD	PYRQ, novel quinolone compound, PCID 16001701	4	4	4

YPD	YPG, obligate respiratory	2	4	4


uORF homology group	uORF length (amino acids)	Conserved sequence features

		Length conserved at N- and C-Termini	N-terminus (amino acids)	Middle (amino acids)	C-terminus (amino acids)	Overall

uORF features conserved between Arabidopsis and rice

1	25–43	C-terminus			SY-rich: 5/14	20–39% STY

2	34–39	C-terminus			KR-rich: 5–6/20	18–24% KR

3	50–54	N- and C-termini	K-rich: 4/9	S-rich: 5–6/6	KR-rich: 4–5/16, SY-rich: 4–5/12	17–23% KR. 22–29% SY

4	52–55	N- and C-termini			SY-rich: 7/30	21–23% STY

5	38–41	N- and C-termini

6	55–68	N-terminus

7	57–105	N-terminus	STY-rich: 6–7/22	KR-rich: 4/5–8

8	61–62	N- and C-termini				CHCH domain, 17% KR

9	17–33	N-terminus

10.1	41	N- and C-termini

11	24–44	C-terminus			KR-rich: 5–6/15	25% KR

12	39–51	N- and C-termini

13	25	N- and C-termini		RS-rich: 10–12/18		40–48% RS

14	29	N-terminus		ST-rich: 4–6/10		14–32% STY

15.1	18–27	N- and C-termini			8/9 hydrophobic

15.3	43–54	N- and C-termini			13/14 completely conserved

16	40–62	C-terminus

17	36–45	C-terminus

18	36–38	Neither

19	30–34	N-terminus				29% ST

uORF features conserved between Arabidopsis paralogs

20	41–43	N- and C-termini	STY-rich: 8–9/27			23% STY

21	87–90	N- and C-termini		ST-rich: 11–12/17–22		22–25% ST

22	25	N- and C-termini

23	69–71	Neither

24	31–34	N- and C-termini

25	25	N- and C-termini

26	22	N-terminus


	Baseline	6-month

	Mean (SD)	Mean (SD)	P value

Knowledge

 General knowledge on health and tobacco use (range: 0–7)	4.5 ± 1.0	5.2 ± 0.7	0.02

 Specific knowledge on smoking-related diseases (range: 0–10)	7.6 ± 2	7.7 ± 1.6	0.8

Attitudes a

 Banning all tobacco advertisement	3.4 ± 0.5	3.3 ± 0.6	0.14

 Recognition of own & professional role in smoking cessation counseling	3.3 ± 0.4	3.2 ± 0.3	0.17

 Bad image of woman smokers	2.97 ± 0.3	3.2 ± 0.3	0.001

Practice in smoking cessation counseling	n (%)	n (%)

 Had practiced	15 (62.5)	12 (55.0)	-

 Among those who had practiced b

 Ask	0.83 (1.0)	0.92 (0.9)

 Advise	1.38 (1.1)	1.38 (0.8)

 Assess	0.92 (1.0)	0.92 (0.9)

 Assist	1.00 (1.1)	1.15 (0.9)

 Arrange	0.42 (0.9)	0.17 (0.4)


 Parameter	 Step size α	 Nr. epochs	 Decay constant λ

	 0.3	 10	N/4


Research procedure	Responder	Definitely Yes (%)	Probably Yes (%)	Probably No (%)	Definitely No (%)

“Drawing 1 extra vial of blood for research purposes when other blood is being obtained for clinical purposes. (Would not require an extra blood draw.)”	Parent by Infant Status	NICU ≤ 31 wks	50	22	15	13

NICU 34-36 wks	45	38	3	13

NICU Term with hypoglycemia	45	45	8	3

Well-Baby Nursery/Mother-Baby Unit (37-42 weeks)	45	43	10	3

Healthcare Provider	66	32	2	0

“Drawing 1 extra vial of blood for research purposes only. (Would require an extra blood draw.)”	Parent by Infant Status	NICU ≤ 31 wks	12	32	37	20

NICU 34-36 wks	28	42	15	15

NICU Term with hypoglycemia	18	33	33	15

Well-Baby Nursery/Mother-Baby Unit (37-42 weeks)	32	33	33	15

Healthcare Provider	22	41	28	10

“2 Echocardiograms (heart ultrasound). These are not associated with any pain, but occasionally some infants can feel slight discomfort”	Parent by Infant Status	NICU ≤ 31 wks	33	55	12	5

NICU 34-36 wks	22	52	12	14

NICU Term with hypoglycemia	18	56	25	0

Well-Baby Nursery/Mother-Baby Unit (37-42 weeks)	30	43	23	3

Healthcare Provider	50	48	2	0

“MRI brain without sedation”	Parent by Infant Status	NICU ≤ 31 wks	20	40	20	20

NICU 34-36 wks	20	25	27	28

NICU Term with hypoglycemia	7	27	40	20

Well-Baby Nursery/Mother-Baby Unit (37-42 weeks)	12	22	42	23

Healthcare Provider	28	38	24	11

“MRI brain with sedation”	Parent by Infant Status	NICU ≤ 31 wks	15	38	27	30

NICU 34-36 wks	12	18	37	33

NICU Term with hypoglycemia	5	21	20	54

Well-Baby Nursery/Mother-Baby Unit (37-42 weeks)	5	20	39	36

Healthcare Provider	3	16	48	33


Ethical view	Emic view (relative frequency) n = 65	Possibilities

Finning[100]	“Fishing that only takes shark fins (63,4%)	“Best monitor”; “Give high fine”

Immature Capture [101]	Fish small sharks (61,9%)	“drop the baby sharks”, put closure, “increase the mesh of the nets”

Bycatch Capture [102]	“Fishing with trawlnet”, “fishnet excess”, “stuck with longline hook in steel” (46,8%)	“forbid trawling”, “control gillnets use”, “forbid longline hooks stuck with Spiral wire Rope use”

Females Capture [70]	“female fishing”; “fish a female carrying a baby shark in the belly” (15,1%)	“Drop females”; “make closure”


	Dietary Group 2

Index	C	LP	R	SEM

Day 3

Initial body weight (g/mouse)	8.5	8.4	8.6	0.10

Final body weight (g/mouse)	10.4 X	7.2 Y	7.4 Y	0.10

Food intake (g/mouse · 3d) 3	7.8 X	4.5 Y	3.6 Y	0.20

Food intake (g/g body weight · d)3	0.19 X	0.13 Y	0.09 Z	0.001

Carcass dry matter (g/100g wet weight)	30.3 X	28.3 Y	27.9 Y	0.30

Carcass lipid (g/100g wet weight)4	9.2 X	5.9 Y	3.4 Z	0.03

Day 14

Initial body weight (g/mouse)	8.3	8.5	8.6	0.08

Final body weight (g/mouse) 4	17.5 X	6.1 Y	6.0 Y	0.02

Food intake (g/mouse · 14d) 5	60.6 X	18.2 Y	12.6 Z	0.01

Food intake (g/g body weight · d)	0.20 X	0.11 Y	0.08 Z	0.002

Carcass dry matter (g/100g wet weight)	32.1 X	28.1 Y	26.5 Z	0.26

Carcass lipid (g/100g wet weight)	10.4 X	4.5 Y	2.7 Z	0.34


Study (Year)LocationReview article cited	Nature of Practice	Amount of Practice	Study Results, Attributes and Limitations

IWAO et al. (1999) [51]Japan/Kyotouncontrolled observational study	Qigong walking = mild and slow walking using all muscles in body Conventional walking = normal walking	Evaluated 90 min post lunch on 3 different days Qigong walking (30–40 min)Conventional walking (30 min)	Plasma glucose decreased in both exercise groups Conventional = 228 to 205 mg/dL; Qigong = 223 to 216 mg/dLCompared with no exercise, 229 mg/dL (p < 0.025)Very short-duration study where subjects served as their own controls. Little information known about subjects.

LIU et al. (2010) [52]Australia/QueenslandPre-post feasibility trial uncontrolled observational study	Kai/Mai Tai Chi/Qigong style - defines qigong as "mind-body movement therapy...most involve combined training of movement, breathing, and mind, with a strong focus on the mind“	12 weeks1–1.5 h 3×/wk with Tai Chi/Qigong instructor; also encouraged to practice at home	Good adherence and high acceptability; Significant reductions with BMI, HbA1c and IRNo subjects were taking medications. Combination of group and individual practice.

HUANG et al. (2012) [53]Taiwan/Kaohsiungquasi-experimental	Defines qigong as breathing training. Qi meaning breath and gong meaning to train. Five Element Gymnastics (FEG) consolidates Qigong, Xiang Gong & Martial Arts with Gymnastics.	16 weeksFEG practiced following DVD 2 ×/day for 20 min each session for 16 weeks with 2 sessions in first week taught by certified fitness instructor and group education sessions at weeks 3, 7, 11 and 14; Control group maintained usual activities	HbA1C change -6.77 (p < 0.01)Included insulin-dependent subjects; however, medications remained same. Combination of instructor led group practice and DVD led at home individual practice.


Name	Expression plasmids	Properties

YJ0	pBS01A	Empty vector

YJ-G01	pYJ-G01	TcGPAT1 expression

YJ-G02	pYJ-G02	TcGPAT2 expression

YJ-L01	pYJ-L01	TcLPAT1 expression

YJ-L02	pYJ-L02	TcLPAT2 expression

YJ-D01	pYJ-D01	TcDGAT1 expression

YJ-D02	pYJ-D02	TcDGAT2 expression

YJ-111	pYJ-111	TcGPAT1, TcLPAT1 and TcDGAT1 gene combination expression

YJ-112	pYJ-112	TcGPAT1, TcLPAT1 and TcDGAT2 gene combination expression

YJ-121	pYJ-121	TcGPAT1, TcLPAT2 and TcDGAT1 gene combination expression

YJ-122	pYJ-122	TcGPAT1, TcLPAT2 and TcDGAT2 gene combination expression

YJ-211	pYJ-211	TcGPAT2, TcLPAT1 and TcDGAT1 gene combination expression

YJ-212	pYJ-212	TcGPAT2, TcLPAT1 and TcDGAT2 gene combination expression

YJ-221	pYJ-221	TcGPAT2, TcLPAT2 and TcDGAT1 gene combination expression

YJ-222	pYJ-222	TcGPAT2, TcLPAT2 and TcDGAT2 gene combination expression


Variable	Sensitivity	Specificity	Positive predictive value	Negative predictive value

B3 criterion	0.44	0.91	0.13	0.87

MSI histology	0.79	0.85	0.20	0.80

MsPath score*	0.86	0.85	0.18	0.82

Tumor infiltrating lymphocytes	0.52	0.65	0.37	0.63

Any mucinous differentiation	0.63	0.69	0.34	0.65

Poor differentiation	0.27	0.89	0.13	0.88

Family history of cancers (B4.B5)	0.64	0.92	0.13	0.87

Revised Bethesda guidelines	0.78	0.77	0.3	0.7

Revised Bethesda guidelines (modified B1, age limit <45 y)	0.78	0.89	0.19	0.80


Words	Mean	SD

Arousal

Negative	5.24	1.49

Positive	4.68	1.47

Neutral	2.77	1.32

Valence

Negative	2.58	0.79

Positive	7.62	0.55

Neutral	5.00	0.34


Characteristics	Survivors (n = 64)	Non-survivors (n = 46)	P

At ICU admission

 Age (years old)	60 [45–69]	63 [57–73]	0.03

 Male sex	49 (76.6)	29 (63)	0.12

 Weight (kg)	70 [60–80]	70 [58–79]	0.84

 Body mass index (kg/m2)	24.6 [20.7–27.8]	24.4 [20.7–28]	0.58

 APACHE II	21 [17–25]	26 [22–29]	0.0007

 Simplified Acute Physiology Score 2	52 [41–60]	57 [45–73]	0.05

 History of congestive heart failure	6 (9.4)	6 (13)	0.54

 Liver cirrhosis	0	4 (8.7)	0.03

 Chronic obstructive pulmonary disease	15 (23.4)	11 (23.9)	0.96

 Chronic kidney disease requiring dialysis	4 (6.3)	5 (10.9)	0.38

 Cancer (<3 months) 	11 (17.2)	5 (10.9)	0.35

 Diabetes mellitus	15 (23.4)	24 (52.2)	0.002

 Immunodepression	16 (25)	8 (17.4)	0.34

At the day of aminoglycoside administration

 Day since admission	1 [0–5]	2 [0–7]	0.32

 Emergent surgery	17 (26.6)	8 (17.4)	0.26

 Sequential Organ Failure Assessment score	9 [7–10]	10 [9–13]	0.004

 Weight (kg)	70 [60–81]	70.5 [60–80]	0.92

 Weight gain since ICU admission (kg)	0 [0–2]	0 [0–3]	0.62

 Extracorporeal membrane oxygenation	7 (10.9)	8 (17.4)	0.33

 Catecholamines	49 (76.6)	40 (87)	0.17

 Norepinephrine (μg/kg/min)	0.26 [0.04–0.61]	0.83 [0.41–1.65]	0.0002

 PaO2/FiO2 ratio	200 [140–280]	147 [103–259]	0.06

 Renal replacement therapy	19 (29.7)	21 (45.7)	0.09

 Glomerular filtration rate (mL/min)	53.5 [29.7–90.4]	29.8 [0–65.9]	0.008

 Lactate level (mmol/L)	1.7 [1.2–3.1]	3.2 [1.4–7]	0.01

 Platelet count (G/L)	205 [105–339]	201 [86–270]	0.47

 Hematocrit level (%)	29.2 [26–31.3]	29.7 [26–32.4]	0.54

 Leucocyte count (G/L)	15.6 [9.4–22.3]	13.4 [7.8–18.7]	0.22

 Glasgow Coma Scale score	15 [14, 15]	15 [12–15]	0.23

 Bilirubin level (mg/dL)	12 [8–17]	145 [9–26]	0.22

 Prothrombin time (%)	72 [57–81]	60 [47–75]	0.01

 Proteinemia (g/L)	58 [49–64]	52 [46–62]	0.1

 Amikacin Cmax between 60 and 80 mg/L	34 (53.1)	13 (28.3)	0.009


Dependent variables	Adjusted R2	Independent variables (partial regression coefficient) b

Tension	0.214***	SOC (−0.408***)

Job demand (quantity) (−0.193**)

Fatigue	0.306**	SOC (−0.390***)

Job demand (quantity) (−0.357***)

Anxiety	0.313***	SOC (−0.352***)

Job demand (quality) (−0.349***)

Low support from supervisor (0.187*)

Depression	0.335***	SOC (−0.411***)

Low support from supervisor (0.197**)

Married (−0.195**)

Job demand (quantity) (−0.158*)

Subjective symptoms	0.092***	SOC (−0.314***)

Vigor	0.395***	SOC (0.275**)

Low job aptitude (−0.206**)

Low support from supervisor (−0.254***)

Self-rated health	0.018*	Physical job load (−0.183**)

Work duration (0.182*)

Low support from colleagues (−0.157*)


Signs and symptoms of Flammer syndrome	Patient 1	Patient 2	Patient 3	Patient 4

1	Do you suffer from cold hands or feet even in summer time?	+	+	+	+

2	Do you have a low blood pressure?	+	–	+	–

3	Are you less thirsty than others?	+	+	–	–

4	If you have to take medications, do you have the feeling that you react strongly to them?	+	Not known	Not known	+

5	Do you suffer from migraines?	+	Not reported	–	Not reported

6	Do you suffer from tinnitus (ringing in your ears)?	Not reported	+	+	+

7	Do you often feel cold when you are not moving for sometime?	+	+	+	+

8	Do you need a relatively long time to fall asleep, especially when you are cold?	+	+	+	+

9	Do you identify smells better than others?	+	Not reported	+	Not known

10	Have you noticed reversible skin blotches (white or red) when you were excited or angry?	+	+	+	+


Group	Type	Model	AUC	Specificity	Sensitivity

Early	Parenclitic	-7.44 (Alpha-centrality)	0.624	1	0.189 ± 0.124

	-0.16 (Pill use)

RDLG	-2.09 (GPC1)	0.663	1	0.163 ± 0.087

Late	Parenclitic	0.07 (Connections to MUC16)	0.904	1	0.803 ± 0.077

RDLG	2.14 (MUC16)	0.904	1	0.767 ± 0.082


 	N = 90

None

No contraceptive use (includes abstinence, withdrawal, celibacy)	49

Pregnant or trying to get pregnant	5

Permanent methods

Tubal ligation, partner vasectomy	6

Long-acting methods

Implanon	6

Depo	5

IUD	1

Reversible methods

The pill	4

Condoms	17*

Diaphragm	0


Layer	Type	Input	Kernel	Output

1	Convolution	28 × 28 × 1	5 × 5	24 × 24 × 32

2	Max pooling	24 × 24 × 32	2 × 2	12 × 12 × 64

3	Convolution	12 × 12 × 64	5 × 5	8 × 8 × 64

4	Max pooling	8 × 8 × 64	2 × 2	4 × 4 × 64

5	Fully connected	4 × 4 × 64	4 × 4	512 × 1

6	Fully connected	512 × 1	1 × 1	2 × 1

7	Softmax	2 × 1	N/A	Result


Home visits to recipients of programme ITNs	N = 13	95% Conf. Int.

# of household ITNs found matched self-report	13/13 (100%)	-

Total # of ITNs found in all visited households	32	-

Mean ITNs per household	32/13 = 2.5	-

 ITNs in working order and mounted	28/32 (88%)	(72 – 95)

 ITNs torn and not mounted	1/32 (3%)	-

 ITNs torn and still mounted	3/32 (9%)	-

Households in which none of ITNs were mounted	3/13 (33%)	(8 – 50)


Centrality measures (Mi)	|PeC ∩ Mi|	|Mi - PeC|	Non-essential proteins in {Mi - PeC}	Percentage of non-essential proteins in {Mi - PeC} with low PeC

Degree Centrality (DC)	18	82	44	54.5%

Betweenness Centrality (BC)	16	84	47	51.1%

Closeness Centrality (CC)	16	84	51	56.9%

Subgraph Centrality(SC)	11	89	59	64.4%

Eigenvector Centrality(EC)	11	89	59	64.4%

Information Centrality(IC)	17	83	47	55.3%

Bottle Neck (BN)	16	84	53	45.3%

Density of Maximum Neighborhood Component (DMNC)	12	88	42	42.9%

Local Average Connectivity-based method (LAC)	34	66	37	59.5%

Sum of ECC (SoECC)	37	63	31	54.8%

Range-Limited Centrality (RL)	17	83	42	54.8%

L-index (LI)	13	87	55	58.2%

Leader Rank(LR)	16	84	46	52.2%

Normalized α-Centrality (NC)	11	89	59	64.4%

Moduland-Centrality(MC)	11	89	57	66.7%


Target of deletion	Animal model	Results of immunization	Reference

Biopterin transporter, LdBT1−/−	Balb/C	Protective immunity, antigen-specific IFN-γ secretion	Papadopoulou et al. (53)

Centrin 1, LdCen−/−	Balb/C mice, hamsters, dogs	Protective immunity against L. donovani and L. braziliensis challenge. Increased IFNγ, IL-2, and TNF producing cells and IFNγ/IL-10 ratio, presence of multifunctional cells	Selvapandiyan et al. (48), Fiuza et al. (58)

Silent information regulatory two single allele deletion, LiSIR2±	Balb/C	Protective immunity, increased antigen-specific IFNγ/IL-10 ratio	Silvestre et al. (55)

Cytochrome c oxidase complex component p27, Ldp27−/−	Balb/C	12-Week survival in host, protective immunity against L. donovani, L. braziliensis, and L. major challenge. Increased IFNγ, IL-2, and TNF producing cells and IFNγ/IL-10 ratio	Dey et al. (49)

Heat shock protein 70, LiHsp70−/−	Balb/C	Cross protection against L. major, high IgG2a relative to IgG1	Carrion et al. (56)


Metric variables	Virginity status	Gender

Femalesa	Malesb

Age at death (wk)	Virgin	99.2 ± 2.4c (7, 141)d	85.2 ± 3.4e (1, 133)

Age at death (wk)	Mated	88.3 ± 5.2 (35, 138)	104.0 ± 3.8 (61, 149)

Total number of litters produced by a dam/stud		8.9 ± 0.7 (2, 16)	10.5 ± 1.1 (1, 19)

Total number of pups at birth produced by a dam/stud		56.8 ± 5.2 (4, 92)	97.2 ± 10.7f (1, 169)

Total number of pups at weaning produced by a dam/stud		52.4 ± 5.0 (3, 88)	92.2 ± 10.1f (1, 162)

Age at last litter (wk)		51.9 ± 2.8 (31, 80)	92.2 ± 4.3g (54, 130)

Time interval between mating & last litter (wk)		34.1 ± 2.8 (6, 55)	40.2 ± 4.3 (2, 78)

Time interval between litters (wk)		3.8 ± 0.1 (3, 5.4)	3.7 ± 0.2 (2, 5.6)

Time interval between last litter & death (wk)		29.2 ± 4.7 (0, 88)	11.8 ± 4.2h (0, 94)


Declaration of minimodel	Explanation

<SimulaDerivative name=“rootGrowthRate” function=“usePath” unit=“cm/day”>	Declaration of a minimodel named rootGrowthRate which uses the plugin “usePath” to simulate a growth rate with the unit cm d−1

<SimulaConstant name=“path” type=“string”> rootGrowth </SimulaConstant>	Declaration of a minimodel named “path” which contains a string of the path to which “rootGrowthRate” needs to be coupled

<SimulaConstant name=“multiplier”> 0.1 < /SimulaConstant>	Declaration of a minimodel named “multiplier” which is a simple constant with which the result of minimodel named by “path” should be multiplied

</SimulaDerivative>	Closing of the declaration of minimodel “rootGrowthRate”, so it is clear that “path” and “multiplier” are owned by it

<SimulaVariable name=“rootGrowth” function=“useName+Rate” integrationFunction=“RungeKutta4” unit=“cm” > 1. </SimulaVariable>	Declaration of a minimodel named rootGrowth, which will use function “useName+Rate” to retrieve data and will integrate that data with the default integration function, RungeKutta4. Start value is 1


Variable	Intervention	Sham	p*

N	24	10	–

Age [years]	57 (12)	65 (12)	0.079

Gender M/F (%)	67/33%	70/30%	0.999

Education [years]	10 (4)	10 (4)	0.869

Affected hemisphere R/L (%)	50/50%	40/60%	0.715

Etiopathogenesis (%)			0.999

Ischemic	71%	70%

Hemorrhagic	29%	30%

Previous stroke events (%)	21%	30%	0.666

Lesion localization (%)			0.735

Cortical	25%	10%

Subcortical	62%	80%

Both	13%	10%

Time from stroke [mos]	41 (39)	37 (32)	0.797

Smoke (%)	25%	10%	0.644

Hypertension (%)	72%	70%	0.999

Diabetes (%)	8%	30%	0.138

Dyslipidemia (%)	38%	40%	0.999

Stroke familiar history (%)	21%	30%	0.666

THERAPY

Antidepressant	71%	40%	0.130

Antihypertensive	58%	60%	0.999

Antiplatelet	79%	70%	0.666

NIBS SEQUENCE

TMS-tDCS	8	–	–

tDCS-TMS	16

SIDE EFFECTS IN 10 SESSIONS**

TMS	4		–

tDCS	6	3

Drop outs (%)	24%	0%	–